[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK181442B1 - Cells capable of producing one or more human milk oligosaccharides (hmos) comprising expression of an invertase, method comprising said cells for biosynthetic production and use of said cells for biosynthetic production; use of an invertase in a biosynthetic production - Google Patents

Cells capable of producing one or more human milk oligosaccharides (hmos) comprising expression of an invertase, method comprising said cells for biosynthetic production and use of said cells for biosynthetic production; use of an invertase in a biosynthetic production Download PDF

Info

Publication number
DK181442B1
DK181442B1 DKPA202270138A DKPA202270138A DK181442B1 DK 181442 B1 DK181442 B1 DK 181442B1 DK PA202270138 A DKPA202270138 A DK PA202270138A DK PA202270138 A DKPA202270138 A DK PA202270138A DK 181442 B1 DK181442 B1 DK 181442B1
Authority
DK
Denmark
Prior art keywords
sucrose
genetically modified
nucleic acid
modified cell
acid sequence
Prior art date
Application number
DKPA202270138A
Other languages
Danish (da)
Inventor
Papadakis Manos
Banke Niels
Original Assignee
Dsm Ip Assets Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets Bv filed Critical Dsm Ip Assets Bv
Priority to PCT/EP2022/063313 priority Critical patent/WO2022243310A1/en
Priority to PCT/EP2022/063314 priority patent/WO2022243311A1/en
Priority to CN202280035391.3A priority patent/CN117321071A/en
Priority to EP22730130.6A priority patent/EP4341277A1/en
Priority to JP2023565529A priority patent/JP2024516207A/en
Priority to EP22730129.8A priority patent/EP4341276A1/en
Publication of DK202270138A1 publication Critical patent/DK202270138A1/en
Application granted granted Critical
Publication of DK181442B1 publication Critical patent/DK181442B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2431—Beta-fructofuranosidase (3.2.1.26), i.e. invertase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present disclosure relates to a genetically modified cell capable of utilizing sucrose as energy and carbon source following the expression of a single heterologous enzyme, which upon expression is translocated from the cytosol and which is capable of hydrolysing non-phosphorylated sucrose into fructose and glucose. The identification of efficient enzymes capable of hydrolysing sucrose in its non-modified form, and which on its own enable the cell to utilize sucrose as a, or as the main and/or sole, carbon and/or energy source, i.e., without the need for multi-gene sucrose utilizing systems comprising several other heterologous polypeptides, such as other enzymes and/or transporters, is highly advantageous, since it allows for cost-effective use of sucrose in large scale production processes.

Description

DK 181442 B1 1
CELLS CAPABLE OF PRODUCING ONE OR MORE HUMAN MILK OLIGOSACCHARIDES (HMOS)
COMPRISING EXPRESSION OF AN INVERTASE, METHOD COMPRISING SAID CELLS FOR
BIOSYNTHETIC PRODUCTION AND USE OF SAID CELLS FOR BIOSYNTHETIC PRODUCTION;
USE OF AN INVERTASE IN A BIOSYNTHETIC PRODUCTION
FIELD
The disclosure relates to a genetically modified cell capable of utilizing sucrose as energy and carbon source following the expression of a single heterologous enzyme, which upon expression is translocated from the cytosol and which is capable of hydrolysing non-phosphorylated sucrose into fructose and glucose.
BACKGROUND
Human milk oligosaccharides (HMO(s)) have become of great interest in the last decade, due to the discovery of their important functionality in human development. Besides their prebiotic properties,
HMO(s) have been linked to additional positive effects, expanding their field of application. The health benefits of HMO(s) have enabled their approval for use in foods, such as infant formulas and foods, and — for consumer health products.
To date, the structures of at least 115 HMO(s) have been determined, and considerably more are probably present in human milk.
Due to the limited availability of HMO(s), an effective commercial, i.e., large scale production, is highly desirable. The manufacturing of large-scale quantities as well as qualities, required for food and medical applications, through chemical synthesis, has yet to be provided. Furthermore, chemical synthetic routes to HMOXs) involve several noxious chemicals, which impose a contamination risk to the final product.
To bypass the drawbacks associated with chemical synthesis of HMO(s), several enzymatic methods and fermentative approaches have been developed. Fermentation based processes have been developed for several HMO(s), such as 2'-fucosyllactose, 3-fucosyllactose, lacto-N-tetraose, lacto-N- neotetraose, 3'-sialyllactose and 6'-sialyllactose. Fermentation based processes typically utilize genetically modified bacterial strains, such as recombinant Escherichia coli (E. coli), or yeast, such as
Saccharomyces cerevisiae (S. cerevisiae).
Biosynthetic production of HMO(s) in modified bacterial strains is a valuable, cost-efficient and large- scale applicable solution for HMO manufacturing. It relies on genetically modified bacteria constructed so as to express the glycosyltransferases needed for synthesis of the desired oligosaccharides and takes advantage of the bacteria’s innate pool of nucleotide sugars as HMO precursors.
Recent developments in biotechnological production of HMO(s) have made it possible to overcome certain inherent limitations of bacterial expression systems. For example, HMO-producing bacterial cells may be genetically modified to increase the limited intracellular pool of nucleotide sugars in the bacteria
DK 181442 B1 2 (WO2012/112777), to improve activity of enzymes involved in the HMO production (WO2016/040531), or to facilitate the secretion of synthesized HMO(s) into the extracellular media (WO2010/142305,
WO2017/042382). Further, expression of genes of interest in recombinant cells may be regulated by using particular promoter sequences or other gene expression regulators, like e.g., as recently — described in WO2019/123324.
The metabolic pathways of such biosynthetic production of HMO(s) require a carbon source which is mainly a simple carbon building block. Typically, glycerol, glucose, or lactose have been used, (see e.g.
WO2001/04341, Priem et al. Glycobiology 12, 235 (2002), Fort et al. Chem. Comm. 2558 (2005),
Drouillard et al. Angew. Chem. Int. Ed. 45, 1778 (2006), WO2010/070104, WO2012/112777, — WO2013/182206, WO2014/048439).
Further, around 50 % of wild-type E. coli are able to utilize sucrose as a, or even as the sole, carbon and energy source, but most of them are pathogenic. However, in some cases, sucrose would be a cheaper sole carbon and sole energy source. It can be directly fermented (either as cane juice or as molasses), or it can be easily made into pure sugar by high-temperature crystallization, whereas glucose has to be — converted from starch by milling and enzymatic hydrolysis. Further, sucrose-based bioprocesses are more environmentally friendly and sustainable than glucose-based bioprocesses. Finally, the lack of a chemically reactive reducing end in the sucrose molecule, leads to a much cleaner impurity profile after heat-sterilisation and fermentation, when compared with glucose. As a result of these primary factors, the associated overall bioprocess cost is decreased relative to that with glucose. In addition, sucrose is highly abundant and readily available.
For this reason, attempts have been made to create de novo non-pathogenic strains of E. coli that can live and grow on sucrose (Suc') (e.g., Sabri et al. Appl. Environ. Microbiol 79, 478 (2013)) and to produce industrially profitable products by them, such as amino acids, biofuel, carotenoids etc. E. coli strains have been engineered by transfer of sucrose catabolic capabilities into non-sucrose-utilizing strains mainly in industry to synthesize chemical materials such as petrochemicals. However, these
Suc” transformants have generally been less productive than Suc strains (Khamduang et al. J. Ind.
Microbiol. Biotechnol. 36, 1267 (2009)). Therefore, complete sucrose utilizing cassette systems have been transferred which in combination confer efficient sucrose catabolism when integrated onto the E. coli chromosome (Bruschi et al. Biotechnol. Adv. 30, 1001 (2012)).
WO02012/007481and WO2009/078687 describes E. coli transformants that express either a sucrose phosphorylase, sucrose-6-phosphate hydrolase or a sucrose invertase in combination with a fructokinase. Thereby, the microorganism is able to produce 2'-fucosyllactose, utilizing sucrose as its main carbon source. Furthermore, W02014/067696 describes an E.coli transformant comprising a csc- gene cluster comprising the genes sucrose permease, fructokinase, sucrose hydrolase, and a transcriptional repressor (genes cscB, cscK, cscA, and cscR, respectively), that enables it to grow on sucrose and to produce fucose.
DK 181442 B1 3
WO2015/197082 describes E. coli that comprises a heterologous PTS-dependent sucrose utilization transport system containing a sucrose specific porin, a sucrose transport protein and a sucrose-6- phosphate hydrolase. The oxidation of glucose-6-phosphate and fructose thus provides a biological energy source by the organism's own metabolic system. Also, glucose-6-phosphate and fructose serve — as carbon source for producing sugar nucleotides in the cell's natural biosynthetic pathway. The so- produced sugar nucleotides are donors for glycosylating carbohydrate acceptors (e.g. lactose), internalized through a specific permease by the cell, and thereby manufacturing oligosaccharides of interest. The glycosylation is mediated by one or more glycosyl transferases which are directly produced by expressing heterologous genes. The organism lacks any enzyme degrading either the acceptor or the oligosaccharide product in the cell.
The present disclosure for the first time shows a genetically modified cell capable of utilizing sucrose as energy and/or carbon source following the expression of a single heterologous enzyme, thus overcoming the need for the expression of multiple proteins and protein complexes in order to enable the utilization of sucrose as an energy and carbon source.
SUMMARY
Presently disclosed is a genetically modified cell capable of utilizing sucrose as energy and carbon source following the expression of a single heterologous enzyme, which upon expression is to a sufficient extent translocated from the cytosol and which is capable of hydrolysing sucrose into fructose and glucose. The genetically modified cell described herein is thus capable of utilizing sucrose as its main, or in some embodiments even as its sole carbon and energy source.
The identification of efficient enzymes capable of hydrolysing sucrose in its non-modified form, and which alone or on its own enable the cell to utilize sucrose as the main and/or the sole, carbon and/or energy source, i.e. without the need for a multi-gene sucrose utilizing cassette system, comprising several other heterologous polypeptides, such as other enzymes and/or transporters, is highly advantageous, since it allows for cost-effective use of sucrose in large scale biosynthesis production processes. It reduces considerably the need and costs associated therewith of the removal of by- products and metabolites from the fermentation product during purification of the final product. A further advantage of the use of a sucrose hydrolysing enzyme capable of hydrolysing sucrose into fructose and glucose on the extracellular or periplasmic side of the genetically modified cell, is that sucrose does not enter the cell, where if in excess sucrose will contribute to metabolic overflow leading to formation of metabolites like lactate, acetate and ethanol which can negatively affect cell growth and production capabilities.
In its broadest sense, the present disclosure thus relates to a genetically modified cell which comprises a heterologous nucleic acid sequence encoding a heterologous polypeptide, which upon expression is at least to a sufficient degree translocated from the cytosol to be located extracellularly, periplasmic and/or membrane-bound or membrane-embedded and which is capable of hydrolysing sucrose into fructose
DK 181442 B1 4 and glucose outside the cell or in the periplasmic space, wherein the expression of said heterologous polypeptide alone or on its own enables the utilization of sucrose as the main and/or the sole, carbon source and/or energy source of said genetically modified cell, without sucrose entering the cytosol of the host cell. The polypeptide is after expression typically located extracellularly and/or in the periplasmic space and/or in the cytosolic membrane. When said heterologous polypeptide is an invertase, it is capable of hydrolysing non-phosphorylated sucrose into fructose and glucose.
Thus, an aspect of the invention relates to a genetically modified cell capable of producing one or more
Human Milk Oligosaccharides (HMOs), which comprises a heterologous nucleic acid sequence encoding a an invertase, wherein said invertase is SacC Agal comprising or consisting of the amino acid sequence of SEQ ID NO: 1 or a functional homologue thereof, having an amino acid sequence which is at least 80 % identical to SEQ ID NO: 1, wherein the cell further comprises at least one additional heterologous nucleic acid sequence(s) encoding one or more functional enzyme(s) with glycosyltransferase activity.
The heterologous nucleic acid sequence can be provided to the cell episomally (i.e., by a multi-copy plasmid) and/or chromosomally (i.e., by genomic integration). It can comprise a single, or multiple copies of the heterologous gene, such as at least two genomically integrated copies of the heterologous nucleic acid sequence encoding the invertase. In embodiments, the heterologous nucleic acid sequence encodes an episomal and/or genomically integrated copy of the invertase.
The heterologous polypeptide is capable of hydrolysing non-phosphorylated sucrose, i.e., sucrose in its non-modified form, into fructose and glucose. In one embodiment, the heterologous polypeptide is an invertase. The heterologous polypeptide on its own does not transport sucrose and it does not encode a complete sucrose utilization system. In another embodiment, the invertase is capable of hydrolysing non-phosphorylated sucrose. An invertase of the present invention is in that regard an invertase capable of hydrolysing sucrose into fructose and glucose in the periplasmic space and/or on the extracellular side of the cell. Furthermore, in embodiments, the expression of said invertase enables utilization of sucrose as the main and/or the sole carbon source and/or as the main and/or the sole energy source of the genetically modified cell of the present invention. In that regard, in embodiments, the genetically modified cell of the present invention does not contain a complete sucrose utilization system.
In addition, in the genetically modified cell the endogenous glucose transport system is fully or partially inactivated. Accordingly, in a preferred embodiment, the pfsG gene of the genetically modified cell, encoding a cytoplasmic-membrane glucose permease is fully or partially inactivated.
In a presently preferred embodiment, a genetically modified cell according to the present disclosure is further capable of producing one or more human milk oligosaccharide(s) (HMO(s)).
In a presently preferred embodiment, the heterologous polypeptide is a glycoside hydrolase family 32 — protein from Avibacterium gallinarum, as shown in SEQ ID NO: 1 (SacC Agal), or a functional
DK 181442 B1 homologue thereof, having an amino acid sequence which is at least 80 %, such as at least 85 %, such as at least 90 %, such as at least 95 % or such as ae least 99 % identical to SEQ ID NO: 1.
The heterologous nucleic acid sequence can further comprise a regulatory element for regulating the expression of the heterologous nucleic acid sequence, comprising e.g., one or more inducible promoter 5 sequence(s) and/or one or more constitutive promoter sequence(s). The regulatory element can be a promoter selected from the group consisting of PmgiB 70UTR SD8, PmgiB 70UTR SDT0O,
PmgiB 54UTR, Plac 70UTR, PmgiB 70UTR SD9, PmgiB 70UTR SD4, PmgiB 70UTR SD5,
PglpF. SD4, PmgiB 70UTR SD7, PmgiB 70UTR, PglpA_70UTR PglpT_70UTR, PglpF, CP6, PosmY,
Pspc, Pbla, Prrn1 and Prrn2 or variants thereof.
The heterologous nucleic acid sequence can further encode a signal peptide capable of enhancing the continuous secretion of said heterologous polypeptide into the periplasm of the genetically modified cell and/or into the fermentation media. In a preferred embodiment, said signal peptide is selected from table 1, and is preferably the signal peptide of SEQ ID NO: 28.
Typically, a genetically modified cell according to any of the preceding claims is a single-celled organism, such as a prokaryotic or a eukaryotic cell. In particular embodiments the genetically modified cell is selected from a yeast cell of the genera Komagataella, Kluyveromyces, Yarrowia, Pichia,
Saccaromyces, Schizosaccharomyces or Hansenula or from a filamentous fungous of the genera
Aspargillus, Fusarium or Thricoderma. Alternatively, in embodiments, the genetically modified cell is selected from the group consisting of Escherichia sp., Bacillus sp., lactobacillus sp. and Campylobacter sp. In particular, a genetically modified cell according to the present disclosure can be Escherichia coli.
The invention also relates to the use of a genetically modified cell according to the present invention, for biosynthetic production. In particular, the invention relates to the biosynthetic production of one or more
HMOXs). In that regard, the present invention relates to a method for the biosynthetic production of one or more HMO(s), the method comprising the steps of: a) providing a genetically modified cell according to the invention, b) culturing the cell of (a) in a suitable cell culture medium, containing sucrose as a carbon source, and c) harvesting the HMO(s) produced in step (b). Accordingly, in a method for the biosynthetic production of one or more HMO(s) of the present invention, the invertase in the genetically modified cell of step a) on its own is capable of hydrolysing sucrose into fructose and glucose on the extracellular side and/or in the periplasmic space of the genetically modified cell, and wherein the expression of said enzyme is sufficient to enable utilization of sucrose as carbon and/or as energy source of said genetically modified cell. Thus, in embodiments, the sucrose in step b) is the main and/or sole carbon source and/or energy source.
Alternatively, the invention also relates to a method for biosynthetic production in a genetically modified host cell capable of producing one or more oligosaccharides and/or polysaccharides, the method comprising the steps of: a) providing a non-sucrose-utilizing (Suc) host cell or a host cell with limited and/or inefficiently ability to utilize sucrose capable of producing the desired biosynthetic product, b) introducing into said host cell a heterologous nucleic acid sequence encoding a invertase, wherein said
DK 181442 B1 6 invertase is SacC Agal comprising or consisting of the amino acid sequence of SEQ ID NO: 1 or a functional homologue thereof, having an amino acid sequence which is at least 80 % identical to SEQ ID
NO: 1, optionally wherein, the ptsG gene of said host cell, encoding a glucose permease is fully or partially inactivated, c) culturing the cell of (b) in a suitable cell culture medium, containing sucrose as — the main and/or the sole, carbon source and/or as the main and/or the sole energy source, and d) harvesting the biosynthetic product produced in step c).
A modified cell according to the present disclosure can be used for the expression of a heterologous polypeptide as described herein, which can be harvested, purified and/or isolated and be used for the in vitro production of fructose and glucose from sucrose.
A modified cell according to the present disclosure can be used to produce fructose and glucose.
A modified cell according to the present disclosure can be used for the biosynthetic production of one or more HMO(s).
The invention thus also relates to the use of an invertase which is capable of hydrolysing sucrose into glucose and fructose, in a biosynthetic production, wherein the invertase is SacC Agal comprising or consisting of the amino acid sequence of SEQ ID NO: 1 or a functional homologue thereof, having an amino acid sequence which is at least 80 % identical to SEQ ID NO: 1. In addition the invertase is capable of hydrolysing non-phosphorylated sucrose into fructose and glucose in the periplasmic space and/or on the extracellular side of the cell used in the biosynthetic production. Accordingly, the invertase of the present invention may also be used in the biosynthetic production of one or more HMOs.
BRIEF DESCRIPTION OF THE FIGURES
Fig. 1
A genetically modified cell capable of utilizing sucrose as energy and carbon source by simply expressing a single heterologous enzyme, as described in the framework of the present disclosure. The possible localizations of such heterologous enzymes are denoted by a numeric indicator: cell exterior (1), periplasm (2) or cytoplasm (3).
Fig. 2
Batch growth profile on sucrose for E. coli cells that do or do not express proteins that enable the utilization of sucrose as the main and/or the sole, carbon source and/or energy source. ScrYA-ScrBR: sucrose utilization technology as described in WO2015/197082, SacC_Msuc & SacA Bsuc: enzymes — used for sucrose hydrolysis as described in WO2009/078687A2, SacC_Agal & Bff: enzymes for sucrose utilization as described in the present disclosure.
Fig. 3
Batch growth profile on sucrose for E. coli cells expressing the enzyme SacC Agal or the sucrose utilization system ScrBRYA. ScrYA-ScrBR: sucrose utilization technology as described in
DK 181442 B1 7
WO2015/197082, SacC Agal (x1, x2, x3): enzymes for sucrose utilization as described in the present disclosure. The copy number of the SacC Agal gene in different strains is provided in the parenthesis; x1 denotes one SacC Agal copy, x2 denotes two SacC Agal copies and x3 denotes three SacC Agal copies.
Fig. 4
Relative growth rate on sucrose in batch mode cultures of strains that do or do not express proteins that enable the utilization of sucrose a, and/or the main and/or the sole, carbon source and/or energy source.
ScrYA-ScrBR: sucrose utilization technology as described in WO2015197082, SacC Msuc &
SacA Bsub: enzymes used for sucrose hydrolysis as described in WO2009078687A2, SacC Agal and
Bff: enzymes for sucrose utilization as described in the present disclosure. The copy number of the
SacC Agal gene in different strains is provided in the parenthesis; x1 denotes one SacC Agal copy, x2 denotes two SacC Agal copies and x3 denotes three SacC Agal copies.
Fig. 5
Relative production of LNnT of an E.coli cell expressing two copies of SacC Agal under control of the — PlgpF promoter (MP9 and MP 10) or under control of the Pscr promoter (MP11 and MP12) as compared to E. coli cells expressing the enzyme or the sucrose utilization system ScrBRYA (MP2) (max expression set to 100%). In addition, MP10 and MP12 have a pfsG gene deletion.
DETAILED DESCRIPTION
The present disclosure provides a novel means to use sucrose as a, and/or the main and/or even the sole carbon and/or energy source in microbial biosynthesis processes. Prior attempts to create e.g.,
Suc” strains of non-pathogenic E. coli that can live and grow on sucrose have generally been less productive than Suc strains and/or necessitated the introduction of complete systems including several heterologous genes into the host cell.
The present disclosure for the first time discloses a genetic modification of a non-sucrose-utilizing (Suc) cell or of an inefficiently sucrose-utilizing cell, which makes the cell capable of utilizing sucrose efficiently as energy and/or carbon source, following the expression of a single heterologous polypeptide. The single heterologous polypeptide upon expression is translocated from the cytosol into the extracellular space and/or to the cytosolic and/or periplasmic membrane and is capable of hydrolysing sucrose into fructose and glucose. The present disclosure thus for the first time discloses a genetically modified cell, — which prior to the modification was non-sucrose-utilizing (Suc), or which prior to the modification was only limited and/or inefficiently able to utilize sucrose, which has become capable of utilizing sucrose as energy and/or carbon source following the expression of a single heterologous polypeptide, which upon expression is translocated from the cytosol into the extracellular space and/or to the cytosolic and/or periplasmic membrane, and which is capable of hydrolysing sucrose into fructose and glucose.
DK 181442 B1 8
An aspect of the invention relates to a genetically modified cell, comprising a heterologous nucleic acid sequence encoding a heterologous polypeptide enzyme, preferably an invertase, which on its own upon expression, is in a sufficient amount located extracellularly, in the periplasm and/or membrane-bound or membrane-embedded, and wherein said heterologous polypeptide enzyme is capable of hydrolysing sucrose into fructose and glucose on the extracellular side and/or in the periplasm of the genetically modified cell, and wherein further the expression of said heterologous polypeptide enzyme is sufficient to enables utilization of sucrose as carbon and/or as energy source of said genetically modified cell. In a preferred embodiment the heterologous polypeptide enzyme is located extracellularly and or in the periplasm of the genetically modified cell.
In that regard, the present invention also relates to a genetically modified cell which comprises a heterologous nucleic acid sequence encoding an invertase, wherein said invertase is SacC Agal comprising or consisting of the amino acid sequence of SEQ ID NO: 1 or a functional homologue thereof, having an amino acid sequence which is at least 80 % identical to SEQ ID NO: 1.
The identification of new efficient polypeptides capable of hydrolysing sucrose, and which on their own — enable the genetically modified prior (Suc') cell, or only limited sucrose-utilizing cell, to utilize sucrose as a, or as the main and/or sole carbon and/or energy source, i.e. without the need for the introduction of other heterologous polypeptides assisting with sucrose utilization into the cell, such as transporters, porins, permeases, kinases and/or phosphotransferase systems (PTS), is highly advantageous, since it allows for cost-effective use of sucrose in large scale biosynthesis production processes. The advantages of using sucrose as carbon source is for example the low cost. Furthermore glucose- degradation products which can be an issue when glucose is used as carbon-source will be avoided, whereas sucrose-based impurities are rarely observed when sucrose is used as carbon-source. Sucrose may also have additional benefits such as enabling proteins to retain their secondary structure and to protect against harmful external factors.
Prior efforts to convert suc” E. coli strains to suc" strains have necessitated the incorporation of several heterologous genes, e.g., referred to as complete sucrose utilizing cassette systems, such as the PTS system, which in combination allows a genetically modified cell to utilize sucrose as sole carbon and/or sole energy source. These systems typically comprise incorporation of one or more porin(s), one or more permease(s) and one or more phospho-glycosyl hydrolase(s). The porin(s) and transporter(s) facilitate the active transport of sucrose across the cell membrane, and once in the cytosol, sucrose undergoes phosphorylation (6-P-sucrose) in order to be recognized by a sucrose-6-P hydrolase, which facilitates hydrolysis of sucrose-6-P into glucose-6-P and fructose, thus allowing for glucose-6-P to be incorporated into the central carbon metabolism. Thus, these systems require incorporation of multiple heterologous genes, rely on active transport of sucrose into the cytosol via heterologous transporters and phosphorylation of sucrose to be recognized by the specific glycoside hydrolase capable of hydrolyzing sucrose-6-P.
Utilization of sucrose
The present disclosure relates to simple and efficient means to provide to a host organism, that does not naturally contain the relevant genes, a hew ability to utilize sucrose or to enhance an already existing but inefficient sucrose utilization capacity.
Thus, a genetically modified cell of the disclosed invention is provided with a single gene encoding a heterologous polypeptide capable of hydrolysing sucrose outside the cytosol of the cell, thereby providing the cell with the capability to catabolically utilize sucrose as a carbon source, as well as an energy source, without transporting the sucrose into the cytosol of the cell.
The gene that enables the cell to utilize sucrose is a heterologous gene (i.e., derived from a different organism and transferred to the genetically modified cell by conventional recombinant DNA manipulation techniques).
Typically, two kinds of sucrose catabolism can be used by Suc' microorganisms. The phosphoenolpyruvate-sugar phosphotransferase (PEP-PTS) system and the non-PTS system. With the phosphoenolpyruvate (PEP)-dependent phosphotransferase system (“PTS”), sucrose is transported across the cytoplasmic membrane via a sucrose-specific PEP-dependent phosphotransferase, while in the non-PTS system, sucrose is taken up by a sucrose permease. Concomitantly, sucrose is then phosphorylated in the cytosol to generate intracellular sucrose-6-phosphate, which is hydrolysed to glucose-6-phosphate and fructose that are then directed into the central carbon metabolism of the cell.
However, the current invention relates to the use of an invertase or a sucrose-6-phosphate hydrolase, which upon expression is translocated from the cytosol to the cytosolic membrane, the periplasmic membrane and/or to the extracellular space and which allows the cell to utilize sucrose as carbon and energy source without the need for transport of the sucrose into the cytosol. Also, the invertase itself does not require the sucrose to be phosphorylated before hydrolysis.
Thus, the current invention facilitates a de novo or at least improved sucrose hydrolysis of sucrose for the host cell, in the cytoplasm, periplasm or in the extracellular medium, thereby providing the cell with a carbon and energy source in the form of glucose and fructose.
The advantage of using a sucrose hydrolysing enzyme capable of hydrolysing sucrose into fructose and glucose on the extracellular side or in the periplasm of the genetically modified cell that is not able to take-up sucrose, is that localized gradients with high concentrations of sugar that appear in fed-batch and continuous processes in large-scale (Lara et al 2006, Molecular Biotechnology 34: p355-381), is not instantly available to the production cells.
Instead, the sucrose is only acted upon by the small fraction of hydrolysing enzymes that are present within the gradient and sucrose is therefore hydrolysed at a very low rate. This in turn postpones sucrose hydrolysis until the sucrose is more evenly distributed in the fermentation vessel and exposed to — alarger fraction of the exported hydrolysing enzyme. The delayed release of glucose and fructose from
DK 181442 B1 10 sucrose results in a reduction or abolishment of gradients of metabolically available sugar, thus reducing or abolishing overflow-metabolism in the cells. Overflow-metabolism, which is induced in large scale fermentations when gradients of carbon-sources appear due to insufficient mixing of the feed, lead to formation of metabolites like acetate and increase in maintenance energy requirement, which in turn — affect cell growth and product yields. The use of a sucrose hydrolysing enzyme of the present invention can therefore lead to a more stable production host with higher product yields in large-scale fermentations.
The present invention shows that this can be even further improved by reducing the cells uptake rate of the extracellularly formed glucose, e.g., by deleting glucose transporter genes such as ptsG encoding the glucose-specific EIICB component of the native E. coli PTS system. Without being bound by theory it is believed that the deletion of ptsG reduces the glucose uptake rate by the cell thereby limiting the formation rate of glucose-6-phosphate in the cell, thus additionally reducing the overflow-metabolism.
The examples clearly demonstrate that the herein for the first-time disclosed approach of using a single polypeptide capable of hydrolysing sucrose into fructose and glucose on the extracellular side or in the periplasm of the genetically modified cell is superior to the use of the PEP-PTS system as described in the prior art.
As sole carbon source
The genetically modified cell of the invention can utilize sucrose as the sole carbon source, thereby being independent of addition of other sugars in the fermentation process. Instead, the cell can utilize the fructose and glucose produced from the hydrolysis of sucrose as a carbon source.
An extracellular, periplasmic and/or membrane-bound or membrane-embedded heterologous polypeptide.
In carrying out the invention, the heterologous nucleic acid encoding a heterologous polypeptide capable of sucrose hydrolysis, may be expressed cytosolic, periplasmic and/or extracellularly, as long as it's functionality in enabling the utilization of sucrose as the main and/or the sole, carbon source and/or energy source in the genetically modified cell of the invention is retained. The functionality of the heterologous polypeptide is that it hydrolyses sucrose and when it is an invertase, it hydrolyses non- phosphorylated sucrose. Upon expression of the heterologous polypeptide, it is translocated to the extracellular media, however, in this process, it may also exert its sucrose hydrolysing function, thus at least to some degree hydrolysing sucrose in the cytosol and/or in the periplasm. Sucrose hydrolysis in the cytosol may occur to a limited extent if passive transport of the sucrose into the cytosol occur before the active polypeptide has been exported to the periplasm or extracellular side of the cell.
When translocated to a membrane according to the present disclosure, the enzyme will either be embedded into said membrane and/or attached thereto. The enzyme can either penetrate the membrane (transmembrane) or associate with one or the other side of a membrane (integral
DK 181442 B1 11 monotopic). The enzyme can be integrally, peripherally, or transiently associated with the cell membrane.
In the present context, a membrane is a periplasmic and/or cytosolic membrane.
In one embodiment, the heterologous polypeptide of the invention is embedded in and/or attached to a membrane, wherein the membrane is a plasma membrane, periplasmic and/or cytosolic membrane. In one embodiment, the membrane is the plasma membrane, and the enzyme is anchored, embedded and/or attached either at the periplasmic, the extracellular and/or the cytosolic side of the membrane.
In the context of the present disclosure, the membrane may be the cytosolic/inner membrane and/or the periplasmic/outer membrane, as long as the membrane in which the polypeptide is embedded and/or attached to allows the polypeptide to exert its function. If the heterologous polypeptide is associated with the cytosolic/inner membrane of the genetically modified cell it is preferably on the side facing the periplasmic space.
The term “which does not encode a sucrose utilization system’.
As described above, the utilization of sucrose as the main and/or the sole carbon and/or energy source may be obtained by expression of a phosphoenolpyruvate-dependent sugar phosphotransferase (PEP-
PTS) system, which is a multicomponent system that requires the interaction of 4 different enzymes. An example is the scr PEP-PTS system (WO2015/197082), where the gene scrÅ codes for the sucrose transport protein Enzyme IIScr that provides intracellular sucrose-6-phosphate from extracellular sucrose via an active transport through the cell membrane and the concomitant phosphorylation. The sucrose specific ScrY porin (encoded by scrY) facilitate the sucrose diffusion through the outer membrane. The ScrB invertase enzyme (encoded by scrB) splits the accumulated sucrose-6-phosphate by hydrolysis to glucose-6-phosphate and fructose. The repressor protein (encoded by scrB) negatively controls the expression of the scrYAB genes and is induced by sucrose or fructose or the E. coli csc
PEP-PTS system described in WO2014/067696 comprising the genes; sucrose permase, fructokinase, sucrose hydrolase, and a transcriptional repressor (genes cscB, cscK, cscA, and cscR, respectively). A
PEP-PTS system is, however, not within the scope of the current invention since it requires expression of multiple different heterologous polypeptides for it to enable a cell which prior to the insertion of the multiple genes was not capable of utilizing sucrose or at least not efficiently capable to utilizing sucrose, i.e., not as the main and/or sole carbon and/or energy source, to be able to utilize sucrose as the main and/or the sole carbon and/or energy source. Therefore, the invention relates to a genetically modified cell as described above, wherein the heterologous nucleic acid sequence does not encode a complete sucrose utilization system, i.e. where the cell does not encode scrYABR or cscBKAR.
Thus, in one embodiment, the invention relates to a genetically modified cell as described above, wherein the genetically modified cell does not express a complete, multicomponent sucrose utilization — system, comprising a porin, a sucrose transporter and an invertase not capable of hydrolysing non- phosphorylated sucrose. In a further embodiment, the invention relates to a genetically modified cell as described above, wherein the genetically modified cell does not comprise one or more heterologous nucleic acid sequences that comprise a sucrose utilization system comprising a porin, a sucrose transporter and an invertase not capable of hydrolysing non-phosphorylated sucrose.
A heterologous polypeptide
As demonstrated in the experimental section, the present disclosure identifies polypeptides of heterologous origin which are on their own capable of enabling the utilization of sucrose as the main and/or the sole carbon source and/or energy source in a genetically modified host cell, prior (Suc’) or only limited or inefficiently sucrose-utilizing, i.e., without the need for the introduction of a heterologous complete sucrose utilizing system, such as but not limited to a complete sucrose utilizing cassette, into — the host cell.
Accordingly, a heterologous polypeptide of the current invention relates to an enzyme which is capable of hydrolysing sucrose on its own. In particular, a heterologous polypeptide of the current invention relates to an enzyme which is capable of hydrolysing non-phosphorylated sucrose.
Typically, said enzyme is an invertase. In particular, said enzyme is an invertase which is capable of exerting its function intracellularly, periplasmic and extracellularly. In particular again, the heterologous polypeptide described herein relates to an invertase which upon expression is translocated from the cytosol into the extracellular space and/or to the cytosolic and/or periplasmic membrane, and which is capable of hydrolysing sucrose, such as non-phosphorylated sucrose, into fructose and glucose outside the cell or in the periplasmic space.
In relation to the invention, the term invertase relates to an enzyme capable of hydrolysing the terminal non-reducing beta-D-fructofuranoside residues in beta-D-fructofuranosides, such as the beta-D- fructofuranoside residue in sucrose as described for the enzyme entry EC 3.2.1.26.
In one embodiment of the invention, the invertase favours hydrolysis of non-phosphorylated sucrose.
In another embodiment of the invention, said enzyme is a sucrose-6-phosphate hydrolase classified as
EC 3.1.B3, which according to the current disclosure surprisingly can function as an invertase hydrolysing non-phosphorylated sucrose into fructose and glucose. Alternatively, said enzyme functions as an extracellular sucrose-6-phosphate hydrolase.
Thereby, the heterologous polypeptide of the present disclosure enables the utilization of sucrose as the main and/or sole carbon and/or energy source by catalysing the generation of glucose and fructose from sucrose extracellularly and/or in the periplasm of the host cell.
The present disclosure discloses two exemplary heterologous polypeptide sequences which allow the utilization of sucrose as energy and carbon source in a cell previously incapable or only inefficiently capable of utilizing sucrose as energy and/or carbon source. As is demonstrated in the experimental section, this is achieved in the absence of any further genetic modifications, intended to otherwise help — to facilitate the utilization of sucrose as energy and/or carbon source.
DK 181442 B1 13
In a presently preferred embodiment, the heterologous polypeptide is the glycoside hydrolase family 32 (GH32) protein from Avibacterium gallinarum, with an amino acid sequence as shown in SEQ ID NO: 1 (SacC_Agal), or a functional homologue thereof, having an amino acid sequence which is at least 70 % such as at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, such as at least 98%, such as at least 99%, or such as at least 99.9 %, identical to SEQ ID NO: 1.
Also disclosed herein is an alternative heterologous polypeptide which is the beta-fructofuranosidase protein from Arthrobacter globiformis IFO 3062, as shown in SEQ ID NO: 2 (Bff), or a functional homologue thereof, having an amino acid sequence which is at least 70 % such as at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, such as at least 98%, such as at least 99%, or such as at least 99.9 %, identical to SEQ ID NO: 2.
SacC_Agal and Bff
The presently identified heterologous polypeptides, capable of carrying out the invention as described, are in the present context identified as "SacC Agal” and as “Bff”.
The polypeptide herein referred to as SacC Agal as shown in SEQ ID NO: 1 is 100% identical to the
GeneBank ID: WP_103853210.1 and is characterized as a glycoside hydrolase and a sucrose-6- phosphate hydrolase, and according to the current disclosure able to function as an invertase hydrolysing unmodified sucrose.
The polypeptide herein referred to as Bff as shown in SEQ ID NO: 2 is 100% identical to the GeneBank
ID: BAD18121.1 and is categorised as a beta-fructofuranosidase protein, and as shown in Example 1 of the present disclosure, it enables the utilization of sucrose as the main and/or the sole, carbon source and as the main and/or the sole energy source of the genetically modified cell of the present disclosure.
In a presently preferred embodiment, the current invention relates to a genetically modified cell expressing a heterologous polypeptide of SEQ ID NO: 1, or a functional homologue of SEQ ID NOs: 1, having an amino acid sequence which is at least 80 %, such as at least 85 %, such as at least 90 %, such as at least 95 %, such as at least 98 % identical to SEQ ID NOs: 1.
In another preferred embodiment, the invention relates to a genetically modified cell comprising a heterologous nucleic acid sequence encoding a heterologous polypeptide, wherein the encoded polypeptide is the glycoside hydrolase family 32 protein from Avibacterium gallinarum, as shown in SEQ
ID NO: 1 [SacC Agall, or a functional homologue thereof, having an amino acid sequence which is at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NO: 1.
Also disclosed herein is a genetically modified cell comprising a heterologous nucleic acid sequence encoding a heterologous polypeptide, wherein the encoded polypeptide is beta-fructofuranosidase protein from Arthrobacter globiformis IFO 3062, as shown in SEQ ID NOs: 2 [Bff], or a functional
DK 181442 B1 14 homologue thereof, having an amino acid sequence which is at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NO: 2.
A functional homologue
A functional homologue of the polypeptide SacC Agal as shown in SEQ ID NO: 1, or of the polypeptide
Bffas shown in SEQ ID NO: 2, may e.g. be obtained by mutagenesis. The functional homologue(s) should have a remaining functionality of at least 5%, such as 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50%, 60%, 70%, 80 %, 90% or 100% compared to the functionality of a polypeptide with an amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 2. The functional homologue can have a higher functionality compared to the functionality of a polypeptide with an amino acid sequence as shown in
SEQ ID NO: 1 and/or SEQ ID NO: 2. A functional homologue of a polypeptide with an amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 2, should enable the utilization of sucrose as the main and/or the sole carbon and as an, the main and/or the sole energy source of the genetically modified cell.
As demonstrated in the experimental section, functionality is easily tested by introducing a heterologous polypeptide according to the present disclosure into a host cell that cannot grow on sucrose, i.e. a (Suc) strain, and then growing the genetically modified strain in a batch mode and under selected cultivation conditions, e.g. but not limited to at 28°C in medium containing e.g. 15 g/L sucrose as the main or the sole carbon source and/or energy source.
To eliminate the possibility that a (Suc) strain does, unbeknown to the skilled person in the art, already comprise several heterologous genes, which are part of but not sufficient as a complete sucrose utilizing cassette systems, or a PEP-PTS system, which in combination with a further heterologous polypeptide would allow a genetically modified cell to utilize sucrose as a, main and/or sole carbon and/or energy source, a simple PCR testing can be performed to identify such components.
A heterologous fusion polypeptide
The heterologous polypeptide of the invention may also be a heterologous fusion polypeptide recombining two or more heterologous polypeptides, wherein for instance one part of a polypeptide is a trans-membrane or membrane embedded polypeptide, and the second part of the recombined polypeptide is a heterologous polypeptide, as mentioned above, capable of hydrolysing sucrose, e.g.,
Bff or SacC Agal. Thus, in one embodiment, the invertase of the invention is recombined into a fusion polypeptide, wherein one fragment directs and/or anchors and/or inserts the fusion polypeptide into a specific cell membrane. According to the invention, the membrane may be the periplasmic membrane and/or the cytosolic membrane.
In an embodiment wherein the heterologous polypeptide is part of a fusion polypeptide, the other part of the fusion polypeptide is not part of the heterologous polypeptide as such and does thus not count when determining amino acid sequence identity as described herein.
DK 181442 B1 15
A signal peptide
A recombined fusion polypeptide according to the present disclosure can e.g., comprise an enzyme and a signal peptide which can function to prompt the host cell to translocate the enzyme after expression in the cytosol. In general, a signal peptide may direct an expressed polypeptide to a specific cellular compartment and/or organelle, to the periplasm or signal for cellular excretion. In the present context, a signal peptide preferably directs the expressed polypeptide to the plasma membrane, the periplasmic membrane, the periplasm, or to cellular excretion.
A signal peptide is typically 16-30 amino acids long and present at the N-terminus of a newly synthesized polypeptide. In relation to the nucleic acid construct of the invention, the signal peptide is encoded by a nucleic acid sequence that may be operably linked to the heterologous nucleic acid sequence encoding a polypeptide according to the invention. The signal peptide may also be a polypeptide tag, with an amino acid sequence comprising more than 30 amino acids.
The signal peptide acts as a polypeptide tag to promote selectively secretion of the polypeptide of the invention, e.g., a polypeptide tag that promotes the secretion of the polypeptide of the invention, i.e., promoting the secretion of Bff and/or SacC_Agal.
In relation to the invention, wherein the encoded polypeptide enables hydrolysis of sucrose, the secretion of the polypeptide into the periplasm or extracellular space is favoured, since sucrose is only capable of permeating from the outside into the cell to a very low degree, which does not or at least only very limited facilitates cellular utilization of sucrose as a carbon and/or energy source.
The signal peptide is typically selected from the group consisting of, but not limited to, signal sequences listed in table 1 below.
Table 1: signal sequences useful for in combination with the heterologous polypeptide of the invention
Signal | Origin | Amino Acid Sequence | SEG ID NO:
LB UE IC i eee eee eee eee eee eres eee eee yveE iB. subtilis — ; MRKSLITLGLASVIGTSSFLIPFTSKTASA = 5 yogM iB. subtilis— MKLRKVLTGSVLSLGLLVSASPAFA 8... yuaB iB subtilis . MKRKLLSSLAISALSLGLLVSAPTASFAAE 7 pel iB. subtilis MKKVMLATALFLGLTPAGANA ~~ 8 oi pelB iB subtilis — ; MKRLCLWFTVFSLFLVLLPGKALG 9
YoaW ;B. subtilis — MKKMLMLAFTFLLALTIHVGEASA 210 i ygXl iB. subtilis: MFKKLLLATSALTFSLSLVLPLDGHAKA 11... pA i B. subtilis MKFVKRRIALVTILMLSVISLFALQPSAKAA 12
PB... ;B. subtilis — ; MKKVLMAFIICLSLILSVLAAPPSGAKA 13 .yoqH…… ; B. subtilis— MKRFILVLSFLSIIVAYPIQTNA 14
YbFO.…... B. subtilis — MKRMIVRMTLPLLIVCLAFSSFSASARA 15...
SacB… ;B. subtilis MNIKKFAKQTVLTFTTALLAGGATQAFA.....16…....../ bls iB subtilis: MPYLKRVLLLLVTGLFMSLFAVTATASA 17
YddT…… ; B. subtilis MRKKRVITCVMAASLTLGSLLPAGYASA 18
YObB iB subtilis : MKRKILLSSALSFGMLISAVPALA 19 pelB_.S.cerevisize | MKYLLPTAAAGLLLLAAQPAMA 20
PhoA i Eco... MKQSTIALALLPLLFTPVTKA 21 mn
JamB i E. COM... … MMITLRKLPLAVAVAAGVMSAQAMA 22...)
DK 181442 B1 16 nce Origin Amino Acid Sequence SEQ ID NO:
OmpA E.coli. MKKTAIAIAVALAGFATVAGA 23 d fhuD E.coli | MSGLPLISRRRLLTAMALSPLLWQMNTAHA 24 .mdoD i FE. CM... : MDRRRFIKGSMAMAAVCGTSGIASLFSQAAFA 125 ;yedOo (E.coli + +—.MTINFRRNALQLSVAALFSSAFMANA 26 ; dsbA E.coli MKKIWLALAGLVLAFSASA PT. d : Af-ss : Alcaligenes : MAKGLVRTGLAAAGLILGWAGAPTHA : 28 :
In an embodiment the heterologous polypeptide is part of a fusion polypeptide comprising a signal sequence, wherein the signal sequence is not part of the heterologous polypeptide as such and does thus not count when determining amino acid sequence identity as described herein.
A nucleic acid construct
The heterologous polypeptide of the invention is expressed from a nucleic acid construct comprising the nucleic acid sequence encoding the individual heterologous polypeptide. The nucleic acid construct of the invention may further comprise additional elements, e.g., regulatory sequences ensuring the proper level of expression of the polypeptide as well as a nucleic acid sequence encoding one or more signal peptide(s), ensuring the translocation and/or proper sorting and/or secretion of the expressed polypeptide of the invention. Thus, the invention also relates to a nucleic acid construct which upon insertion into a (Suc') host cell, or into a host cell only inefficiently utilizing sucrose, enables said genetically modified cell to utilize sucrose as the main and/or the sole, carbon source and/or energy source.
A nucleic acid construct according to the present disclosure may be a part of a vector DNA. In another embodiment, the nucleic acid construct is an expression cassette/cartridge that is integrated in the genome of a host cell. Accordingly, in the present context the term “nucleic acid construct” means an artificially constructed segment of nucleic acid, in particular a nucleic acid segment, which is intended to be introduced into a host cell, e.g., a microbial cell. In the context of the invention, the nucleic acid construct comprises a recombinant and/or heterologous nucleic acid sequence coding for a heterologous polypeptide.
Typically, the recombinant and/or heterologous nucleic acid sequence essentially comprises one or more non-coding nucleic acid sequence(s) comprising a regulatory nucleic acid sequence, such as, but not limited to a promoter nucleic acid sequence and one or more coding nucleic acid sequence(s) encoding a gene of interest, e.g. a sucrose hydrolysing enzyme which upon insertion into a (Suc) host cell, or into a host cell only inefficiently utilizing sucrose, enables said genetically modified cell to utilize sucrose as the main and/or the sole, carbon source and/or energy source, preferably as the main and/or the sole carbon source and/or energy source.
In addition, the recombinant and/or heterologous nucleic acid sequence can further comprise a non- coding and/or coding sequence useful for production of a human milk oligosaccharide (HMO) in a
DK 181442 B1 17 genetically modified cell, such as, but not limited to, coding for a glycosyltransferase. Alternatively, said non-coding and/or coding sequence useful for production of an HMO in a genetically modified cell can be introduced and/or can have been introduced in the host cell by another nucleic acid sequence. In one embodiment the genetically modified cell comprises at least one recombinant glycosyltransferase — selected from the group of enzymes having the activity of an a-1,2-fucosyltransferase, a-1,3- fucosyltransferase, a-1,3/4-fucosyltransferase, a-1,4-fucosyltransferase a-2,3-sialyltransferase, a-2,6- sialyltransferase, B-1,3-N-acetylglucosaminyltransferase, B-1,6-N-acetylglucosaminyltransferase, B-1,3- galactosyltransferase and B-1,4-galactosyltransferase.
The term "heterologous"
In relation to the current invention, the term "heterologous" refers to a polypeptide, amino acid sequence, nucleic acid molecule, nucleic acid sequence or nucleotide sequence that is foreign to a cell or organism, i.e., a polypeptide, amino acid sequence, nucleic acid molecule, nucleic acid sequence or nucleotide sequence that does not naturally occur in said cell or organism. A "heterologous sequence" or a "heterologous nucleic acid" or "heterologous polypeptide", as used herein, is one that originates from a source foreign to the particular host cell (e.g., from a different individual, strain or species), or, if it originates from the same source, is modified from its original form. Thus, a heterologous nucleic acid operably linked to a promoter is from a source different from that from which the promoter was derived, or, if from the same source, is modified from its original form. The heterologous sequence may be stably introduced, e.g., by transfection, transformation, conjugation or transduction, into the genome of the microbial host cell, thus rendering the host cell a genetically modified host cell. Techniques may be applied which will depend on the host cell as well as the sequence to be introduced. Various techniques are known to a person skilled in the art and are, e.g., disclosed in Sambrook et a/., Molecular Cloning: A
Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).
In that regard, a nucleic acid construct according to the present disclosure is in a presently preferred embodiment a nucleic acid construct that comprises, a) a nucleic acid sequence encoding a heterologous polypeptide which upon expression is located extracellularly, periplasmic and/or membrane-bound or membrane-embedded and which is capable of hydrolysing sucrose into fructose and glucose, wherein the expression of said polypeptide enables utilization of sucrose as the main and/or the sole carbon and/or as the main and/or the sole energy source of a genetically modified cell, and b) a nucleic acid sequence comprising regulatory element(s), capable of modulating the expression of said nucleic acid sequence, and optionally c) a nuclei acid sequence encoding a signal peptide enabling the continuous secretion of said polypeptide into the periplasm of the genetically modified cell and/or into the fermentation media.
DK 181442 B1 18
In one embodiment, a nucleic acid construct according to the present disclosure, comprises a nucleic acid sequence encoding a heterologous polypeptide as shown in SEQ ID NO: 1.
Also disclosed herein is a nucleic acid construct of the present disclosure comprises a nucleic acid sequence encoding a heterologous polypeptide as shown in SEQ ID NO: 2.
In a preferred embodiment, the nucleic acid construct according to the present invention comprises, a) a nucleic acid sequence encoding an invertase, wherein said invertase is SacC Agal comprising or consisting of the amino acid sequence of SEQ ID NO: 1 or a functional homologue thereof, having an amino acid sequence which is at least 80 % identical to SEQ ID
NO: 1, and b) a nucleic acid sequence comprising regulatory element(s), capable of modulating the expression of said nucleic acid sequence, and optionally c) a nuclei acid sequence encoding a signal peptide enabling the continuous secretion of said polypeptide into the periplasm of the genetically modified cell and/or into the fermentation media.
In one embodiment, the regulatory element in b) is a promoter sequence.
In a presently preferred embodiment, the nucleic acid construct according to the present invention comprises, a) a nucleic acid sequence encoding an invertase, wherein said invertase is SacC Agal comprising or consisting of the amino acid sequence of SEQ ID NO: 1 or a functional homologue thereof, having an amino acid sequence which is at least 80 % identical to SEQ ID
NO: 1, and b) a nucleic acid sequence comprising regulatory element(s), capable of modulating the expression of said nucleic acid sequence wherein the regulatory element comprises one or more inducible promoter sequence(s) and/or one or more constitutive promoter sequence(s) selected from the group consisting of PmgilB 70UTR SD8, PmgiB 70UTR SD10,
PmglB 54UTR, Plac 70UTR, PmgiB 70UTR SD9, PmgiB 70UTR SD4, PmgiB 7O0UTR SDS,
PglpF SD4, PmgiB 70UTR SD7, PmgIB_70UTR, PglpA 70UTR PglpT 70OUTR, PglpF, CP6,
PosmY, Pspc, Pbla, Prm1 and Prm2, preferably selected from PglpF and variants thereof, and optionally c) a nuclei acid sequence encoding a signal peptide wherein the signal peptide is selected from table 1, preferably the signal peptide of SEQ ID NO: 28.
DK 181442 B1 19
Furthermore, the nucleic acid construct of the invention may be integrated into the genome of the genetically modified cell, or it may be comprised in an expression vector, such as in a bacterial plasmid, an artificial chromosome, a phagemid and/or another viral vector.
As used herein, the terms "nucleic acid" and "polynucleotide" refer to a deoxyribonucleotide or a ribonucleotide polymer in either single- or double-stranded form, and unless otherwise limited, encompass known analogues of natural nucleotides that hybridize to nucleic acids in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence includes the complementary sequence thereof.
A heterologous nucleic acid sequence
In one embodiment, the nucleic acid construct of the invention encodes a polypeptide which is glycoside hydrolase family 32 protein from Avibacterium gallinarum, as shown in SEQ ID NO: 1 [SacC_Agal], or a functional homologue thereof, having an amino acid sequence which is at least 80 % identical to SEQ ID
NO: 1. Thus, the nucleic acid construct comprises a nucleic acid sequence of SEQ ID NO: 3 [SacC Agall, or a nucleic acid sequence having at least 70 % sequence identity to SEQ ID NO: 3 [SacC Agall, such as at least 75 %, such as at least 80 %, such as at least 85 %, such as at least 90 %, such as at least 95 %, or such as at least 99 % sequence identity to SEQ ID NO: 3 [SacC Agall.
In one embodiment the nucleic acid sequence encoding a polypeptide of SEQ ID NO: 1 [SacC_Agal], or a functional homologue thereof, having an amino acid sequence which is at least 80 % identical to SEQ
ID NO: 1 [SacC Agall, is a nucleic acid sequence of SEQ ID NO: 3 [SacC Agal].
Also disclosed herein, is a construct, wherein the encoded polypeptide is beta-fructofuranosidase protein from Arthrobacter globiformis IFO 3062, as shown in SEQ ID NOs: 2 [Bff], or a functional homologue thereof, having an amino acid sequence which is at least 80 % identical to SEQ ID NO: 2.
Thus, also disclosed herein is the nucleic acid construct which comprises a nucleic acid sequence of
SEQ ID NO:4 [Bff], or a nucleic acid sequence having at least 70 % sequence identity to SEQ ID NO: 4 [Bff], such as at least 75 %, such as at least 80 %, such as at least 85 %, such as at least 90 %, such as at least 95 %or such as at least 99 % sequence identity to SEQ ID NO: 4 [Bff]. In one embodiment the nucleic acid sequence encoding a polypeptide of SEQ ID NO: 2 [Bff], or a functional homologue thereof, having an amino acid sequence which is at least 80 % identical to SEQ ID NO: 2 [Bff], is a nucleic acid sequence of SEQ ID NO: 4 [Bff].
Determining sequence identity
The term “sequence identity of [a certain] %” in the context of two or more nucleic acid or amino acid sequences means that the two or more sequences have nucleotides or amino acids in common in the given percent when compared and aligned for maximum correspondence over a comparison window or designated sequences of nucleic acids or amino acids (i.e. the sequences have at least 90 percent (%) identity). Percent identity of nucleic acid or amino acid sequences can be measured using a BLASTn or
DK 181442 B1 20
BLASTp sequence comparison algorithm with default parameters, or by manual alignment and visual inspection (see e.g. http://www.ncbi.nlm.nih.gov/BLAST/). This definition also applies to the complement of a test sequence and to sequences that have deletions and/or additions, as well as those that have substitutions. An example of an algorithm that is suitable for determining percent identity and for alignment is the BLAST 2.2.20+ algorithm, which is described in Altschul et al. Nucl. Acids Res. 25, 3389 (1997). BLAST 2.2.20+ is used to determine percent sequence identity for the nucleic acids and/or amino acids of the invention. Software for performing BLAST analyses is publicly available through the
National Center for Biotechnology Information (http:/www.ncbi.nlm.nih.gov/). Examples of commonly used sequence alignment algorithms are:
CLUSTAL Omega (5tp:/fwaw. ebi ac. uk/Toois/msa/ciustalof),
EMBOSS Needle (iito: /uww sb ac uk/Toolsfosafemboss needie/),
MAFFT (hittoffmafitebre jofalignment/server)), or
MUSCLE (htin:/fwww ebl.ac.uk/Toolsimsa/muscie/).
Preferably sequence identity between two amino acid sequences is determined using the Needleman- — Wunsch algorithm (Needleman and Wunsch, 1970, J. Mo/. Biol. 48: 443-453) as implemented in the
Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software
Suite, Rice et al., 2000, Trends Genet. 16: 276-277,), preferably version 5.0.0 or later (available at https://www.ebi.ac.uk/Tools/psa/emboss needle/). The parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EBBLOSUM62 (EMBOSS version of 30 BLOSUM®G62) substitution matrix.
The output of Needle labelled "longest identity" (obtained using the -nobrief option) is used as the percent identity and is calculated as follows: (Identical Residues x 100)/(Length of Alignment - Total
Number of Gaps in Alignment).
For purposes of the present invention, the sequence identity between two nucleotide sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1 970, supra) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular
Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277), 10 preferably version 5.0.0 or later. The parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the
DNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix. The output of Needle labelled "longest identity" (obtained using the -nobrief option) is used as the percent identity and is calculated as follows: (Identical Deoxyribonucleotides x 100)/(Length of Alignment — Total Number of Gaps in
Alignment).
One or more copies of said heterologous nucleic acid sequence
A single copy of the construct according to the invention may be sufficient to enable a genetically modified cell to utilize sucrose as the main and/or the sole carbon source and/or energy source, and to achieve the otherwise desired effects according to the invention as disclosed. Accordingly, in some preferred embodiments, the invention relates to a nucleic acid construct and/or a genetically modified cell comprising one, two, three, or more copies of a heterologous nucleic acid sequence, of a regulatory element and/or of a signal peptide.
In some embodiments the single copy of the nucleic acid construct is preferred.
In such an embodiment, the invention relates to a genetically modified cell according to the present disclosure, wherein the heterologous nucleic acid sequence encodes a single copy of a heterologous polypeptide capable of hydrolysing sucrose into fructose and glucose.
Further, the inventors disclose herein the effects of including one or more copies of a construct comprising a regulatory element and a heterologous nucleic acid sequence encoding the polypeptides
Bff or SacC_Agal, on the capability of a genetically modified cell to utilize sucrose as the main and/or the sole carbon source and/or energy source, as can be seen from Example 2.
A nucleic acid construct of the invention may comprise one or more copies of the nucleic acid sequences encoding the polypeptides of the invention; thus, it may also comprise one or more copies of the one or more regulatory element(s) and/or one or more nucleic acid sequences encoding one or more signal peptide(s).
Thus, in one embodiment of the invention, the nucleic acid construct of the invention is a nucleic acid construct, comprising one or more copies of said heterologous nucleic acid sequence.
The more than one heterologous nucleic acid sequences may be identical or different.
Accordingly, in one embodiment of the invention the genetically modified cell comprises at least two copies of the heterologous nucleic acid sequence encoding the polypeptide SacC Agal, such as 2, 3 or 4 genomically integrated copies of a heterologous nucleic acid sequence encoding the polypeptide
SacC Agal.
An alternative way of increasing the capability of a genetically modified cell to utilize sucrose as the main and/or the sole carbon source and/or energy source can also be to place the nucleic acid sequence under control of a strong promoter.
In one embodiment of the present invention the nucleic acid sequence encoding the polypeptides Bff or
SacC Agal are under control of a promoter which is at least 20%, such as at least 50% stronger than the PglpF promoter in table 6.
In a preferred embodiment the nucleic acid sequence encoding the polypeptide SacC Agal are under control of a promoter selected from the group consisting of: PmgiB 70UTR SD8, PmgiB 70UTR SD10,
PmgIB 54UTR, Plac 70UTR, PmgiB 70UTR SD9, PmgiB 70UTR SD4, PmgiB 7O0UTR SDS,
PglpF SD4, PmgiB 7O0UTR SD7, PmgiB 70UTR, PglpA 70UTR and PglpT_70UTR (shown in table 6).
When the nucleic acid construct of the invention comprises more than one regulatory element, the regulatory element may or may not be operably linked with the heterologous nucleic acid sequence encoding the one or more polypeptide(s) of the invention, or the nucleic acid sequence encoding one or
DK 181442 B1 22 more signal peptide(s). Also, when the nucleic acid construct of the invention comprises more than one heterologous nucleic acid sequences as described above, the nucleic acid construct of the invention may or may not comprise one or more nucleic acid sequence encoding a signal peptide, which may or may not be operably linked to the heterologous nucleic acid sequence of the invention.
In that sense, the nucleic acid construct may be constructed in a way, wherein the sequences are encompassed in the following sequence: regulatory element, nucleic acid sequence encoding the signal peptide and heterologous nucleic acid encoding a polypeptide. The nucleic acid sequence encoding the signal peptide may also be absent, or there may be several copies of either of the elements, or they may be shuffled and appear in a different sequence. — The term "operably linked" as used herein, shall mean a functional linkage between one nucleic acid and a second nucleic acid sequence. This could for instance be a nucleic acid sequence comprising a regulatory element which affects transcription and/or translation of the nucleic acid corresponding to the second sequence.
A regulatory element for regulating the expression
The nucleic acid construct of the invention may comprise regulatory elements enabling the controlled overexpression of endogenous or heterologous and/or synthetic nucleic acid sequences. The term “regulatory element”, comprises promoter sequences, signal sequence, and/or arrays of transcription factor binding sites, which sequences affect transcription and/or translation of a nucleic acid sequence operably linked to the regulatory element.
Regulatory elements are found at transcriptional and post-transcriptional levels and further enable molecular networks at those levels. For example, at the post-transcriptional level, the biochemical signals controlling mRNA stability, translation and subcellular localization are processed by regulatory elements. RNA binding proteins are another class of post-transcriptional regulatory elements and are further classified as sequence elements or structural elements. Specific sequence motifs that may serve — as regulatory elements are also associated with mRNA modifications. A variety of DNA regulatory elements are involved in the regulation of gene expression and rely on the biochemical interactions involving DNA, the cellular proteins that make up chromatin, and transcription factors.
Promoters and enhancers are the primary genomic regulatory components of gene expression.
Promoters are DNA regions within 1-2 kilobases (kb) of a gene's transcription start site (TSS); they contain short regulatory elements (DNA motifs) necessary to assemble RNA polymerase transcriptional machinery. However, transcription is often minimal without the contribution of DNA regulatory elements located more distal to the TSS. Such regions, often termed enhancers, are position-independent DNA regulatory elements that interact with site-specific transcription factors to establish cell type identity and regulate gene expression. Enhancers may act independently of their sequence context and at distances — of several to many hundreds of kb from their target genes through a process known as looping. In
DK 181442 B1 23 relation to the present disclosure regulator elements may or may not be post-translational regulators or they may or may not be translational regulators.
In one embodiment of the invention the regulatory element comprises one or more elements capable of enhancing the expression of the heterologous nucleic acid sequence according to the invention.
In a presently preferred embodiment, the regulatory element capable of regulating the expression of the heterologous nucleic acid of the invention is a promoter sequence.
A promoter sequence
The term "promoter" designates a nucleic acid sequence which usually precedes a heterologous nucleic acid sequence encoding a polypeptide in a nucleic acid construct and provides a site for initiation of the transcription into mRNA. Collectively referred to as "promoter " or "control" nucleic acid sequences, these sequences which precede a selected heterologous nucleic acid sequence encoding a polypeptide (or series of sequences) in a functional nucleic acid construct, cooperate to determine whether the transcription (and eventual expression) of a heterologous nucleic acid sequence encoding a polypeptide will occur. Nucleic acid sequences which "follow" a heterologous nucleic acid sequence encoding a polypeptide in a nucleic acid construct and provide a signal for termination of the transcription into
MRNA are referred to as transcription "terminator" sequences.
In general, a promoter may comprise homologous, heterologous or synthetic nucleic acid sequences, and may be a recombinant nucleic acid sequence, recombining two or more nucleic acid sequences or same or different origin as described above, thereby generating a homologous, heterologous or synthetic nucleic promoter sequence, and/or a homologous, heterologous or synthetic nucleic regulatory element. A wide selection of promoter sequences derived from the PglpF, PglpA, PglpT, PgatY, Plac and PmglB promoter systems are described in detail WO2019/123324 and WO2020/255054, some of which are shown in table 6.
Table 6 — Selected promoter sequences
TT eh [TR to PglpF*
DK 181442 B1 24 to PgipF"
PgipA 16UTR | 38-64% | middle |WO2019123324 | 50] "The promoter activity is assessed in the LacZ assay described below with the PglpF promoter run as positive reference in the same assay. To compare across assays the aclivity is calculated relative to the
PglpF promoter, 3 range indicates results from multiple assays.
The promoter may be of heterologous origin, native to the genetically modified cell ort may be a recombinant promoter, combining heterologous and/or native elements.
One way to increase the production of a product may be fo regulate the production of the desired enzyme activity used fo produce the product, such as the glycosyliransferases or enzymes involved in the biosynthetic pathway of the glycosyl donor. 140 Increasing the promoter strength driving the expression of the desired enzyme may be one way of doing this. The strength of a promoter can be assed using a lacZ enzyme assay where B-galactosidase activity is assayed as described previously (see e.g. Miller JH. Experiments in molecidar genetics, Cold spring
Harbor Laboratory Press, NY, 1972). Briefly the cells are diluted in Z-buffer and permeabilized with sodium dodecyl sulfate {0.1%} and chioroform, The LacZ assays is performed at 30°C. Samples are 18 preheated, the assay initiated by addition of 200 ul ortho-nitro-phenyi-B-galaclosidase (4 mg/ml} and stopped by addition of 500 ul of 1 M Na:CO: when the sample had turned slightly vellow, The release of ortho-nitrophena! is subsequently determined as the change in optical densily at 420 nm. The specific activities are reported in Miller Units (MU) [A420/tmin"møi ASOOY. A regulatory slement with an activity above 10,000 MU is considered strong and a regulatory element with an activity below 3.000 MU is considered weak, what is in between has intermediate strength. An example of a strong regulatory element is the PgipF promoter with an activity of approximately 14.000 MU and an example of a weak promoter is Plac which when induced with IPTG has an activity of approximately 2300 MU.
Thus, in one embodiment of the invention, the invention relates to a nucleic acid construct, comprising one or more regulatory elements which are one or more promoter sequences. Preferably a promoter sequence from table 6. In the light of the present disclosure, a promoter promotes the expression of
SacC Agal or Bff.
A promoter sequence is a sequence capable of promoting and/or enhancing the expression of a nucleic acid sequence encoding a polypeptide, in a constitutive or inductive manner.
The invention relates to a nucleic acid construct as described above, wherein the one or more promoter sequence(s) is/are one or more inducible promoter(s) and/or one or more constitutive promoter(s).
An inducible promoter
In one embodiment of the invention, the one or more promoter sequences is/are one or more inducible promoter(s). Accordingly, in another embodiment the one or more promoter sequences is/are one or more constitutive promoter(s).
In a preferred embodiment of the invention, the invention relates to a nucleic acid construct as described above comprising a regulatory element, wherein the regulatory element is a promoter selected from the — group consisting of, PgatY 70UTR, PglpF, PgipF SD1, PgipF SD10, PgipF SD2, PgipF SD3,
PglpF. SD4, PglpF SD5, PgipF SD6, PgipF SD7, PgipF SD8, PglpF SD9, Plac 16UTR, Plac,
PmglB 70UTR, PmgiB 7OUTR SD4, Pxyl, Ptet, , PsacB, PxylA, ProR, PnitA, PBAD, PT7, Ptac, PL,
PR, PnisA and Pb. The group of promoters is not exhaustive. More examples are illustrated in prior art e.g., Carrol et. al., Applied and Environmental Microbiology, June 2005, p. 3077—3084.
The nucleic acid construct of the invention may thus comprise a promoter sequence operably linked to a heterologous nucleic acid sequence encoding a heterologous polypeptide of the invention, thereby enhancing the expression of said nucleic acid sequence upon a specific cue, such as pH, nutrient, sugar related, regulatory proteins, ions such as phosphate, organic chemicals such as IPTG or carbohydrates, physical parameters such as temperature, pH, signalling molecules, short nucleic acids, toxin related or similar intra- or extracellular related cues.
Thus, in one embodiment of the invention, the invention relates to a nucleic acid construct as described above comprising a regulatory element, wherein the regulatory element comprises an inducible promoter which is a sucrose inducible promoter, such as but not limited to Pscr and/or PsacB.
In a further preferred embodiment of the invention, the invention relates to a nucleic acid construct as described above comprising a regulatory element, wherein the regulatory element is the inducible promoter Pscr.
In another embodiment of the invention, the invention relates to a nucleic acid construct as described above, that comprises an inducible promoter, wherein the inducible promoter is PgipF (SEQ ID NO: 42) and/or Plac (SEQ ID NO: 51). In yet another embodiment of the invention, the invention relates to a nucleic acid construct as described above, that comprises an inducible promoter, wherein the inducible promoter is PgipF (SEQ ID NO: 42)
A constitutive promoter
In another preferred embodiment of the invention, the invention relates to a nucleic acid construct as described above comprising a regulatory element, wherein the regulatory element comprises a constitutive promoter.
When the regulatory element comprises a constitutive promoter, i.e., which constitutively promotes the expression of a heterologous nucleic acid encoding a heterologous polypeptide according to the invention, the constitutive promoter may be a strong or a weak constitutive promoter. Typical constitutive promotors of the present disclosure are mentioned in Liang et al, Activities of Constitutive Promoters in
Escherichia coli, J. Mol. Biol. (1999) 292, 19-37, Yim et al, Molecular Characterization of the Promoter of osmY, a rpoS-DependentGene, JOURNAL OF BACTERIOLOGY, Jan. 1994, p. 100-107, and Jensen and Hammer, Appl Environ Microbiol. 1998 Jan;64(1):82-7.
In that regard, in a preferred embodiment of the invention, the invention relates to a nucleic acid construct as described above, that comprises a constitutive promoter, wherein the constitutive promoter is selected from the group consisting of, CP6, PosmY, Pspc, Pbla, Prm1 and Prrn2.
A signal peptide
In one embodiment of the invention, the nucleic acid construct comprises a nucleic acid sequence encoding a signal peptide as described above. Thus, in a preferred embodiment of the invention, a nucleic acid construct according to the present disclosure comprises a nucleic acid sequence encoding a signal peptide, wherein the signal peptide is placed upstream or downstream of the heterologous nucleic acid encoding a polypeptide capable of hydrolysing sucrose. Preferably, the signal peptide is selected from Table 1, and even more preferably the signal peptide is SEQ ID NO:28.
A genetically modified cell — The present disclosure relates to a genetically modified cell which comprises a heterologous nucleic acid sequence encoding an extracellular, periplasmic and/or membrane-bound or membrane-embedded heterologous polypeptide which is an enzyme capable of hydrolysing sucrose into fructose and glucose, wherein the expression of said polypeptide enables utilization of sucrose as the main and/or the sole carbon source and/or energy source. Alternatively, as the main and/or the sole carbon and/or as the main and/or the sole energy source, or even as sole carbon source and as sole energy source of said genetically modified cell. Preferably, the heterologous enzyme that is capable of hydrolysing sucrose into fructose and glucose, can use unmodified sucrose, such as non-phosphorylated sucrose, as substrate.
One aspect of the present invention is a genetically modified cell which comprises a heterologous nucleic acid sequence encoding a heterologous enzyme which on its own is capable of hydrolysing sucrose into fructose and glucose on the extracellular side of the genetically modified cell, and wherein the expression of said enzyme is sufficient to enable utilization of sucrose as carbon and/or as energy source of said genetically modified cell.
As discussed above uneven sucrose gradients in the fermentation process may lead to metabolic stress of the genetically modified cell. To circumvent this, the parts of the endogenous glucose transport system can be fully or partially inactivated, to slow the uptake of glucose from the media down.
Thus, in an embodiment, the endogenous glucose transport system of the genetically modified cell is fully or partially inactivated.
Accordingly, in a preferred embodiment the genetically modified cell of the present invention does not contain a functional ptsG gene and does therefore not produce the glucose-specific EIICB component (UniProt P69786) of the native E. coli glucose PTS system. In another preferred embodiment the ptsG gene, encoding a cytoplasmic-membrane glucose permease is fully or partially inactivated. A cell with a non-functional ptsG gene has a reduced or limited glucose uptake compared to a cell with a functional ptsG gene. The ptsG can either be deleted from the cell, alternatively it can be edited resulting in loss of — function of the ptsG gene or gene product, or which abolishes the function of the polypeptide encoded by the mutated ptsG gene. Suitable methods for such editing of genes are well known to the person skilled in the art.
Genetically modified cells can in general contain one or more genes that are not present in the native (not genetically engineered) form of the cell. Techniques for introducing exogenous nucleic acid molecules/sequences and/or inserting exogenous nucleic acid molecules/sequences (recombinant, heterologous) into a cell's hereditary information for inserting, deleting or altering the nucleic acid sequence of a cell's genetic information are known to the skilled artisan.
Genetically modified cells can contain one or more genes that are present in the native form of the cell, wherein said genes are modified and re-introduced into the microbial cell by artificial means.
The term "genetically modified" also encompasses cells that contain a nucleic acid molecule being endogenous to the cell that has been modified without removing the nucleic acid molecule from the cell.
Such modifications include those obtained by gene replacement, site-specific mutations, and related techniques.
Genetically modified cells of the invention can be provided using standard methods of the art e.g., those described in the manuals by Sambrook et al., Wilson & Walker, "Maniatis et al., and Ausubel et al.
Host cells
Regarding the genetically modified cell, there are, in principle, no limitations; they may be eubacteria (gram-positive or gram-negative) or archaebacteria, as long as they allow genetic manipulation for
DK 181442 B1 28 insertion of a gene of interest and can be cultivated on a manufacturing scale. Preferably, the host cell has the property to allow cultivation to high cell densities.
In general, a suitable host organism is a host cell that does not naturally contain said relevant genes, so as to confer on said recipient organism a new ability to utilize sucrose or to enhance an already existing, limited sucrose utilization capacity.
Examples of said host organisms include a wide variety of microorganism that do not have a native ability to utilize sucrose, or that utilize sucrose poorly. The only limitation is that the recipient organism must be capable of being genetically altered (by genetic engineering, mating, transduction, transformation, etc.), such that the sucrose utilization gene of the invention may be installed in the host strain.
Non-limiting examples of bacterial host cells that are suitable for recombinant industrial production of an
HMOXs) according to the invention could be Erwinia herbicola (Pantoea agglomerans), Citrobacter freundii, Campylobacter sp, Pantoea citrea, Pectobacterium carotovorum, or Xanthomonas campestris.
Bacteria of the genus Bacillus may also be used, including Bacillus subtilis, Bacillus licheniformis,
Bacillus coagulans, Bacillus thermophilus, Bacillus laterosporus, Bacillus megaterium, Bacillus mycoides, Bacillus pumilus, Bacillus lentus, Bacillus cereus, and Bacillus circulans. Similarly, bacteria of the genera Lactobacillus and Lactococcus may be engineered using the methods of this invention, including but not limited to Lactobacillus acidophilus, Lactobacillus salivarius, Lactobacillus plantarum,
Lactobacillus helveticus, Lactobacillus delbrueckii, Lactobacillus rhamnosus, Lactobacillus bulgaricus,
Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus casei, Lactobacillus reuteri, Lactobacillus jensenii, and Lactococcus lactis. Streptococcus thermophiles and Proprionibacterium freudenreichii are also suitable bacterial species for the invention described herein. Also included as part of this invention are strains, engineered as described here, from the genera Enterococcus (e.g., Enterococcus faecium and Enterococcus thermophiles), Bifidobacterium (e.g., Bifidobacterium longum, Bifidobacterium infantis, and Bifidobacterium bifidum), Sporolactobacillus spp., Micromomospora spp., Micrococcus spp., Rhodococcus spp., and Pseudomonas (e.g., Pseudomonas fluorescens and Pseudomonas aeruginosa).
Non-limiting examples of fungal host cells that are suitable for recombinant industrial production of a heterologous product are e.g., yeast cells, such as Komagataella phaffii, Kluyveromyces lactis, Yarrowia — /ipolytica, Pichia pastoris, and Saccaromyces cerevisiae or filamentous fungi such as Aspargillus sp,
Fusarium sp or Thricoderma sp, exemplary species are A. niger, A. nidulans, A. oryzae, F. solani, F. graminearum and T. reesei.
In one or more embodiments, the genetically engineered cell is selected from the group consisting of E. coli, C. glutamicum, L. lactis, B. subtilis, S. lividans, P. pastoris and S. cerevisiae.
In one or more exemplary embodiments, the genetically engineered cell is B. subtilis.
In one or more exemplary embodiments, the genetically engineered cell is S. Cerevisiae or P pastoris.
DK 181442 B1 29
In one or more exemplary embodiments, the genetically engineered cell is Escherichia coli.
In one or more exemplary embodiments, the invention relates to a genetically engineered cell, wherein the cell is derived from the E. coli K-12 strain or DE3. E. coli K-12 strains are well known in the art (such as EMG2, MG1655, W3110, W3350, C800, and DH5a), which is the strain background for the vast — majority of genetic engineering work done in E. coli, ATCC 8739 (E. coli C), ATCC 11303 (E. coli B),
BL21 (see New England Biolabs catalog, 2007-2008) and derivatives of these strains.
In another embodiment of the present disclosure, the genetically modified cell can be selected from a group of Suc* microbial cells that in the absence of the nucleic acid sequence encoding a polypeptide conferring the capability of sucrose hydrolysis, are less and/or suboptimally capable of utilizing sucrose as carbon and energy source, and wherein the transferring of the nucleic acid sequence encoding a polypeptide according to the present disclosure enables the already Suc microbial cells to better utilize sucrose as carbon and energy source. In said embodiment, the selected Suc' microbial cells can further be engineered to in addition to the introduction of the nucleic acid sequence encoding a polypeptide — according to the present disclosure increase the expression of their endogenous sucrose invertase/hydrolase gene. A microbial cell according to said embodiment can be selected from the group consisting of Suc' Saccharomyces cerevisiae and Suc* Bacillus subtilis.
Genetic integration
Integration of the heterologous nucleic acid of interest comprised in the construct (expression cassette) into the genome can be achieved by conventional methods, e.g. by using linear cartridges that contain flanking sequences homologous to a specific site on the chromosome, as described for the attTn7-site (Waddell C.S. and Craig N.L., Genes Dev. (1988) Feb;2(2):137-49.); methods for genomic integration of nucleic acid sequences in which recombination is mediated by the Red recombinase function of the phage A or the RecE/RecT recombinase function of the Rac prophage (Murphy, J Bacteriol. (1998);180(8):2063-7; Zhang et al., Nature Genetics (1998) 20: 123-128; Muyrers et al., EMBO Rep. (2000) 1(3): 239-243); methods based on Red/ET recombination (Wenzel et al., Chem Biol. (2005), 12(3):349-56.; Vetcher et al., Appl Environ Microbiol. (2005);71(4):1829-35); or positive clones, i.e., clones that carry the expression cassette, can be selected e.g. by means of a marker gene, or loss or gain of gene function.
Expression of the heterologous polypeptide may in one embodiment be obtained from episomal integration, i.e. the nucleic acid encoding the heterologous polypeptide may be inserted into a nucleic acid construct, as described above, which is then subsequently comprised in a plasmid or in another chromosomal independent expression vector, wherein the expression vector might is, at some instances, capable of integrating into the chromosome, it is however not required to do so in order to — obtain expression of the heterologous nucleic acid encoding a heterologous polypeptide of the invention.
Examples of episomes are for instance transposons and insertion sequences.
In the scope of the invention as disclosed, the term “genomically integrated” refers to the integration of a heterologous nucleic acid into the chromosome or into an endogenous plasmid, thus being integrated into the genome of the genetically modified cell of the invention.
Thus, in a preferred embodiment, the invention relates to a genetically modified cell as described above, wherein the heterologous nucleic acid sequence encodes an episomal and/or genomically integrated copy of a heterologous polypeptide capable of hydrolysing sucrose into fructose and glucose.
In one embodiment, the heterologous nucleic acid sequence encoding the heterologous polypeptide according to the invention is integrated into the genome of the genetically modified cell in a stable manner. In another embodiment, the heterologous polypeptide according to the invention is introduced to the genetically modified cell in a transient manner.
A cell which is capable of producing a biosynthetic product
A biosynthetic product in context of the present invention is a compound which is either directly expressed from one or more heterologous genes inserted into a host cell, or one that is produced through utilization of one or more metabolic pathways of the cell and/or one or more enzymatic activities that are engineered to produce a compound of interest. Biosynthetic products can for example be proteins, peptides, lipids, fatty acids, oligosaccharides, polysaccharides, polyesters or vitamins.
Biosynthetic produced proteins or polypeptides are for example biopharmaceutical compounds such as antibodies, vaccines, cytokines, blood factors, enzymes, hormones and growth factors, or industrial compounds such as enzymes. These are generally produced by inserting a recombinant gene(s) that that encode the desired protein or polypeptide into the host cell.
In that regard, the invention also relates to a polypeptide enzyme for use in a biosynthetic production, wherein the polypeptide enzyme is an invertase capable of hydrolysing sucrose into glucose and fructose and is the polypeptide enzyme SacC Agal comprising or consisting of the amino acid sequence of SEQ ID NO: 1 or a functional homologue thereof, having an amino acid sequence which is at least 80 %, such as at least 85 %, such as at least 90 %, such as at least 95 % or such as at least 99 % identical to SEQ ID NO: 1. In an embodiment the polypeptide enzyme is for use in the biosynthetic production of one or more oligosaccharides and/or polysaccharides. In a further embodiment the polypeptide enzyme is for use in the biosynthetic production of one or more HMOs.
Biosynthetically produced oligosaccharides and polysaccharides are for example human milk oligosaccharides (HMOs) or biopolymers. These are generally produced by inserting genes encoding enzymes that can produce the desired compounds based on precursor molecules provided to the cell or produced by synthetic pathways in the host cell (which may also be genetically engineered).
The present invention also relates to a genetically modified cell which comprises a heterologous nucleic acid sequence encoding a heterologous enzyme which on its own is capable of hydrolysing sucrose into
DK 181442 B1 31 fructose and glucose on the extracellular side of the genetically modified cell, and wherein the expression of said enzyme is sufficient to enable utilization of sucrose as carbon and/or as energy source of said genetically modified cell, wherein said cell further comprises one or more recombinant genes that allow it to produce a biosynthetic product of interest.
A cell which is capable of producing human milk oligosaccharides (HMO)
The present disclosure relates to improved and efficient means to biosynthetically produce HMO(s) in modified bacterial strains for large-scale applicable solutions for HMO manufacturing. It relies on genetically modified bacteria constructed so as to express the glycosyltransferases needed for synthesis of the desired oligosaccharides and takes advantage of the bacteria’s innate pool of nucleotide sugars as HMO precursors.
The invention therefore also relates to the use of a genetically modified cell or a nucleic acid construct according to the invention as disclosed, for the biosynthetic production of one or more HMO(s).
For the genetically modified cell according to the present disclosure to be capable of producing one or more HMO(s), it requires multiple genetic modifications. Some of these modifications require the inclusion of glycosyl transferases, which enables the biosynthesis of one or more HMO(s) essentially from lactose and a carbon donor, such as an activated sugar nucleotide.
Activated sugar nucleotides
Each activated sugar nucleotide generally comprises a phosphorylated glycosyl residue attached to a nucleoside, and the specific glycosyl transferase enzyme accepts only the specific sugar nucleotide.
Thus, preferably the following activated sugar nucleotides are involved in the glycosyl transfer: UDP-GIc,
UDP-Gal, UDP-GIcNAc, UDP-GalNAc, UDP-glucuronic acid, GDP-Man, GDP-Fuc and CMP-sialic acid, particularly those selected from the group consisting of UDP-Gal, UDP-GIcNAc, GDP-Fuc and CMP- sialic acid.
The genetically modified cell according to the present disclosure possesses a biosynthetic pathway to — the above-mentioned activated sugar nucleotides, that is, it has one or more sets of genes encoding one or more enzymes responsible for the synthesis of one or more activated glycosyl nucleotides, ready for glycosylation in glycosyl transferase mediated reaction in the cell, when cultured. The sets of genes are either naturally present in the cell or introduced into the cell by means of genetic integration as described in detail above, of the nucleic acid sequences encoding the relevant genes. The biosynthetic production of the activated glycosyl nucleotides by the cell takes place under the action of enzymes involved in the biosynthetic pathway of that respective sugar nucleotide stepwise reaction sequence starting from a carbon source, in the current disclosure the sole carbon source is sucrose (for a review for monosaccharide metabolism see e.g. H. H. Freeze and A. D. Elbein: Chapter 4: Glycosylation precursors, in: Essentials of Glycobiology, 2" edition (Eds. A. Varki et al.), Cold Spring Harbour
Laboratory Press (2009)).
DK 181442 B1 32
It should be emphasized, that cellular biosynthetic production of the activated sugar nucleotides by the genetically modified cell via its own biosynthetic pathway is advantageous compared to in vitro versions of transfer glycosylation, as it avoids using the very expensive sugar nucleotide type donors added exogenously, hence the donors are formed by the cell in situ and the phosphatidyl nucleoside leaving — groups are recycled in the cell.
According, to the invention, extracellular or periplasmic sucrose may enter the cell with the aid of a general sugar permease, or it may be diffused into the periplasm from the extracellular medium, or it may be located close to the cell in the extracellular medium, where, according to the invention, the sucrose is hydrolysed by the invertase to glucose and fructose, followed by uptake of glucose and fructose through respective permeases and/or phosphorylation of the glucose and/or fructose, making then activated sugars, thus enabling their use in cellular metabolism and glycolysis, thus allowing sucrose to act as sole carbon and sole energy source of the genetically modified cell.
An HMO
The term "human milk oligosaccharide" or "HMO" in the present context means a complex carbohydrate found in human breast milk (for reference, see Urashima et al.: Milk Oligosaccharides. Nova Science
Publisher (2011); or Chen, Adv. Carbohydr. Chem. Biochem. 72, 113 (2015)). The HMO(s) have a core structure comprising a lactose unit at the reducing end that can be elongated by one or more B-N-acetyl- lactosaminyl and/or one or more B-lacto-N-biosyl units, and this core structure can be substituted by an a-L-fucopyranosyl and/or an a-N-acetyl-neuraminyl (sialyl) moiety. In this regard, the non-acidic (or neutral) HMO(s) are devoid of a sialyl residue, and the acidic HMO(s) have at least one sialyl residue in their structure. The non-acidic (or neutral) HMO(s) can be fucosylated or non-fucosylated. Examples of such neutral non-fucosylated HMO(s) include lacto-N-triose II (LNT-II) lacto-N-tetraose (LNT), lacto-N- neotetraose (LNNT), lacto-N-neohexaose (LNnH), para-lacto-N-neohexaose (pLNnH), para-lacto-N- hexaose (pLNH) and lacto-N-hexaose (LNH). Examples of neutral fucosylated HMO(s) include 2'- — fucosyllactose (2'-FL), lacto-N-fucopentaose | (LNFP-I), lacto-N-difucohexaose I (LNDFH-I), 3- fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose II (LNFP-II), lacto-N-fucopentaose Ill (LNFP-III), lacto-N-difucohexaose III (LNDFH-III), fucosyl-lacto-N-hexaose II (FLNH-II), lacto-N- fucopentaose V (LNFP-V), lacto-N-difucohexaose II (LNDFH-II), fucosyl-lacto-N-hexaose | (FLNH-I), fucosyl-para-lacto-N-hexaose | (FPLNH-I), fucosyl-para-lacto-N-neohexaose II (F-pLNnH II) and fucosyl- — lacto-N-neohexaose (FLNnH). Examples of acidic HMO(s) include 3'-sialyllactose (3'-SL), 6'- sialyllactose (6'-SL), 3-fucosyl-3'-sialyllactose (FSL), 3'-O-sialyllacto-N-tetraose a (LST a), fucosyl-LST a (FLST a), 6'-O-sialyllacto-N-tetraose b (LST b), fucosyl-LST b (FLST b), 6-O-sialyllacto-N-neotetraose (LST c), fucosyl-LST c (FLST c), 3'-O-sialyllacto-N-neotetraose (LST d), fucosyl-LST d (FLST d), sialyl- lacto-N-hexaose (SLNH), sialyl-lacto-N-neohexaose | (SLNH-I), sialyl-lacto-N-neohexaose II (SLNH-II) — and disialyl-lacto-N-tetraose (DSLNT). In the context of the present disclosure lactose is not regarded as an HMO species.
DK 181442 B1 33
Thus, in one embodiment, the one or more HMO(s) produced by the genetically modified cell is/are selected from the group consisting of lacto-N-triose II (LNT-II) lacto-N-tetraose (LNT), lacto-N- neotetraose (LNNT), lacto-N-neohexaose (LNnH), para-lacto-N-neohexaose (pLNnH), para-lacto-N- hexaose (pLNH), lacto-N-hexaose (LNH), 2'-fucosyllactose (2'-FL), lacto-N-fucopentaose | (LNFP-I), — lacto-N-difucohexaose | (LNDFH-I), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N- fucopentaose II (LNFP-II), lacto-N-fucopentaose III (LNFP-III), lacto-N-difucohexaose III (LNDFH-III), fucosyl-lacto-N-hexaose II (FLNH-II), lacto-N-fucopentaose V (LNFP-V), lacto-N-difucohexaose Il (LNDFH-II), fucosyl-lacto-N-hexaose | (FLNH-I), fucosyl-para-lacto-N-hexaose I (FPLNH-I), fucosyl-para- lacto-N-neohexaose II (F-pLNnH II), fucosyl-lacto-N-neohexaose (FLNnH), 3”-sialyllactose (3'-SL), 6'- sialyllactose (6'-SL), 3-fucosyl-3'-sialyllactose (FSL), 3'-O-sialyllacto-N-tetraose a (LST a), fucosyl-LST a (FLST a), 6'-O-sialyllacto-N-tetraose b (LST b), fucosyl-LST b (FLST b), 6-O-sialyllacto-N-neotetraose (LST c), fucosyl-LST c (FLST c), 3'-O-sialyllacto-N-neotetraose (LST d), fucosyl-LST d (FLST d), sialyl- lacto-N-hexaose (SLNH), sialyl-lacto-N-neohexaose | (SLNH-I), sialyl-lacto-N-neohexaose II (SLNH-II) and disialyl-lacto-N-tetraose (DSLNT).
In another embodiment of the invention said one or more HMO(s), is one or more HMO(s) according to formula 1,
HO OR4 OH
QO Q
O Y
R:30 RO
OR» OH wherein Y is OH,
Riis fucosyl or H,
R2 is fucosyl or H,
R3 is selected from H, sialyl, N-acetyl-lactosaminyl and lacto-N-biosyl groups, wherein the N-acetyl- lactosaminyl group can carry a glycosyl residue comprising one or more N-acetyl-lactosaminyl and/or one or more lacto-N-biosyl groups; each of the N-acetyl- lactosaminyl and lacto-N-biosyl groups can be substituted with one or more sialyl and/or fucosyl residue,
R4 is selected from H, sialyl and N-acetyl-lactosaminyl groups optionally substituted with a glycosyl residue comprising one or more N-acetyl-lactosaminyl and/or one or more lacto-N-biosyl groups; each of the N-acetyl-lactosaminyl and lacto-N-biosyl groups can be substituted with one or more sialyl and/or fucosyl residue, provided that at least one of the R2, R2, R3 and R4 groups is/are different from H.
Genetic modifications to produce one or more human milk oligosaccharide(s) (HMO(s))
Besides a modulated metabolism, the genetically modified cell of the invention may encompass further modifications that enables it to produce one or more human milk oligosaccharide(s). In an especially preferred embodiment, the cell is capable of producing one or more human milk oligosaccharide(s) (HMO(s)).
Above-mentioned modifications relate to metabolic engineering as well as introduction and expression of functional enzymes that enable the production of said one or more HMO(s) from a starting material, that is often lactose.
Thus, the ability of a cell to produce one or more HMO(s) combined with its ability to utilize sucrose as a carbon and as an energy source and/or main carbon and main energy source, and/or sole carbon and sole energy source, requires multiple genetic modifications, thus said genetically modified cell of the invention, in order to satisfy the invention as disclosed herein, comprises a heterologous nucleic acid sequence encoding a heterologous polypeptide capable of hydrolysing sucrose, said polypeptide having an amino acid sequence which is at least 80 %, more preferably at least 90 %, more preferably at least 95% and even more preferably at least 99 % sequence identity to SEQ ID NO: 1.
Further, the invention relates to a genetically modified cell optimized for the production of one or more particular oligosaccharides, in particular one or more particular HMO(s), said cell comprising a heterologous nucleic acid encoding a polypeptide having at least 80 %, such as at least 90 % sequence identity, preferably at least 95 %, more preferably at least 97 %, more preferably at least 98 %, and even more preferably at least 99 % sequence identity to the amino acid sequence of SEQ ID NO: 1.
Accordingly, one embodiment of the invention relates to a genetically modified cell capable of producing one or more Human Milk Oligosaccharides (HMO(s)), wherein said genetically modified cell comprises a heterologous nucleic acid sequence encoding a polypeptide capable of hydrolysing sucrose, said nucleic acid sequence having an nucleic acid sequence which at least 80 % more preferably at least 90 — % and even more preferably at least 95 %, such as 99% sequence identity to SEQ ID NO: 1.
As the production of one or more HMO(s), in a genetically modified cell capable of utilizing sucrose as a carbon and as an energy source, or the main carbon and the main energy source or the sole carbon and the sole energy source, further requires one or more functional enzymes, these are described in detail in the below paragraphs. — B-galactosidase
A host suitable for the HMO production, e.g. E. coli, may comprise an endogenous B-galactosidase gene or an exogenous B-galactosidase gene, e.g. E. coli comprises an endogenous lacZ gene (e.g.,
GenBank Accession Number V00296 (Gl:41901)). For the purposes of the invention, an HMO-producing host cell is genetically manipulated to either not comprise any B-galactosidase gene or to comprise a B- galactosidase gene that is inactivated. The gene may be inactivated by a complete or partial deletion of
DK 181442 B1 35 the corresponding nucleic acid sequence from the bacterial genome, or the gene sequence is mutated in the way that it is not transcribed, or, if transcribed, the transcript is not translated or if translated to a protein (i.e. B-galactosidase), the protein does not have the corresponding enzymatic activity. In this way the HMO-producing bacterium accumulates an increased intracellular lactose pool which is beneficial for — the production of HMOs.
Functional enzymes in biosynthetic production of one or more HMO(s)
As described above, for the cell to be capable of synthesizing one or more HMO(s), the genetically modified cell of the invention must comprise at least one additional heterologous nucleic acid, besides the heterologous nuclei acid enabling utilization of sucrose as the main and/or the sole carbon source and/or as the main and/or the sole energy source, wherein the additional heterologous nucleic acid sequence(s) encodes one or more functional enzyme(s) with glycosyltransferase activity. The glycosyltransferase gene may be integrated into the genome (by chromosomal integration) of the genetically modified cell, or alternatively, it may be comprised in a plasmid and expressed as plasmid- borne, as described for the heterologous nucleic acid sequence of the invention. If two or more — glycosyltransferases are needed for the genetically modified cell to be capable of producing an HMO, e.g. LNT or LNnT, two or more heterologous nucleic acids encoding different enzymes with glycosyltransferase activity may be integrated into the nucleic acid construct of the invention or it may be individual nucleic acid sequences, which may be integrated in the genome and/or expressed from a plasmid, e.g. a B-1,3-N-acetylglucosaminyltransferase (a first heterologous nucleic acid sequence encoding a first glycosyltransferase) in combination with a B-1,3-galactosyltransferase (a second heterologous nucleic acid sequence encoding a second glycosyltransferase) for the production of LNT, where the first and second heterologous nucleic acid sequences can independently from each other be integrated chromosomally or on a plasmid or they can be combined into a nucleic acid construct, optionally comprised in the nucleic acid construct of the invention also comprising the features described above.
In one preferred embodiment, both the first and second heterologous nucleic acids encoding one or more glycosyltransferases are stably integrated into the chromosome of the genetically modified cell; in another preferred embodiment the first and second heterologous nucleic acids encoding one or more glycosyltransferases are integrated independently of the heterologous nucleic acid sequence encoding the heterologous polypeptide of the invention. In a further embodiment, the first and second heterologous nucleic acids encoding one or more glycosyltransferases are integrated into the nucleic acid construct of the invention as disclosed. In another embodiment at least one of the heterologous nucleic acid sequence(s) encoding the glycosyltransferase(s) are plasmid-borne.
A protein/enzyme with glycosyltransferase activity (glycosyltransferase) may be selected in different embodiments from enzymes having the activity of a-1,2-fucosyltransferase, a-1,3-fucosyltransferase, a- 1,3/4-fucosyltransferase, a-1,4-fucosyltransferase a-2,3-sialyltransferase, a-2,6-sialyltransferase, 3-1,3-
N-acetylglucosaminyltransferase, B-1,6-N-acetylglucosaminyltransferase, B-1,3-galactosyltransferase and B-1,4-galactosyltransferase. For example, the biosynthetic production of 2'-FL requires that the modified cell expresses an active a-1,2-fucosyltransferase enzyme; for the production of 3-FL the modified cell needs expression of an active a-1,3-fucosyltransferase enzyme; for the production of LNT the modified cell need to express at least two glycosyltransferases, a 3-1,3-N- — acetylglucosaminyltransferase and a B-1,3-galactosyltransferase; for the production of 6'-SL the modified cell has to express an active a-2,6-sialyltransferase enzyme and a pathway for CMP-sialic acid synthesis; for the production of 3'SL the genetically modified cell has to express an active a-2,3- sialyltransferase enzyme and a pathway for CMP-sialic acid synthesis. Some non-limiting embodiments of proteins having glycosyltransferase activity, which can be encoded by the recombinant genes comprised by the production cell, can be selected from non-limiting examples of Table 2.
Table 2 Glycosyltransferases suitable for HMO production
Protein Sequence ou om | Bienes "FO example
B-1,3-N- LNT II, LNT, LNnT, LNFP-I, LNFP-II,
IgtA_Nm eT acetygucosamny- | LNFP-IIl, LNFP-V, LNFP-VI, LNDFH-I, — ; transferase LNDFH-II, pLNH, F-pLNH I, pLNnH
B-1,3-N- LNT II, LNT, LNnT, LNFP-I, LNFP-II,
IgtA_Nm_MC58 AAF42258.1 acety g ucosam ny - LNFP-IIl, LNFP-V, LNFP-VI, LNDFH-I, transferase LNDFH-II, pLNH, F-pLNH I, pLNnH
B-1,3-N- LNT II, LNT, LNnT, LNFP-I, LNFP-II,
IgtA Hd AAN05638.1 acety g ucosam ny - LNFP-IIl, LNFP-V, LNFP-VI, LNDFH-I, transferase LNDFH-II, pLNH, F-pLNH I, pLNnH
B-1,3-N- LNT II, LNT, LNnT, LNFP-I, LNFP-II,
IgtA_Ng_PID2 AAK70338.1 acety g ucosam ny - LNFP-IIl, LNFP-V, LNFP-VI, LNDFH-I, transferase LNDFH-II, pLNH, F-pLNH I, pLNnH
B-1,3-N- LNT II, LNT, LNnT, LNFP-I, LNFP-II, tå Ng NOCPTT ACF31229.1 acety g ucosam ny - LNFP-IIl, LNFP-V, LNFP-VI, LNDFH-I, transferase LNDFH-II, pLNH, F-pLNH I, pLNnH
B-1,3-N- LNT II, LNT, LNnT, LNFP-I, LNFP-II,
IgtA Past AAK02595.1 acety g ucosam ny - LNFP-IIl, LNFP-V, LNFP-VI, LNDFH-I, transferase LNDFH-II, pLNH, F-pLNH I, pLNnH
B-1,3-N- LNT II, LNT, LNnT, LNFP-I, LNFP-II,
IgtA Nc EEZ72046.1 acety g ucosam ny - LNFP-IIl, LNFP-V, LNFP-VI, LNDFH-I, transferase LNDFH-II, pLNH, F-pLNH I, pLNnH
B-1,3-N- LNT II, LNT, LNnT, LNFP-I, LNFP-II,
IgtA_Nm_87255 ELK60643.1 acety g ucosam ny - LNFP-IIl, LNFP-V, LNFP-VI, LNDFH-I, transferase LNDFH-II, pLNH, F-pLNH I, pLNnH
B-1,3-N- LNT II, LNT, LNnT, LNFP-I, LNFP-II,
HD0466 WP 010944479.1 acety g ucosam ny - LNFP-IIl, LNFP-V, LNFP-VI, LNDFH-I, transferase LNDFH-II, pLNH, F-pLNH I, pLNnH
B-1,3-N- LNT II, LNT, LNnT, LNFP-I, LNFP-II,
PmnagT WP_014390683.1 acety g ucosam ny - LNFP-IIl, LNFP-V, LNFP-VI, LNDFH-I, transferase LNDFH-II, pLNH, F-pLNH I, pLNnH
B-1,3- LNT, LNFP-I, LNFP-II, LNFP-V, LNDFH-
Cvb3galT WP_080969100.1 ga actosy transferase I, LNDFH-II, pLNH, F-pLNH I
B-1,4- LNnT, LNFP-IIl, LNFP-VI, pLNH |, F- gal? Hp/HP0826 | WP 001262061.1 ga actosy transferase pLNH I, pLNnH galT_Nm/ B-1,4- LNnT, LNFP-IIl, LNFP-VI, pLNH |, F-
IgtB AAF42257.1 ga actosy transferase pLNH I, pLNnH
B-1,3- LNT, LNFP-I, LNFP-Il, LNFP-V, LNDFH- wbgO WF 000582563.1 ga actosy transferase I, LNDFH-II, pLNH, F-pLNH I
ER wo cn
B-1,3- LNT, LNFP-I, LNFP-II, LNFP-V, LNDFH- cpslBJ AB050723.1 ga actosy transferase I, LNDFH-II, pLNH, F-pLNH I
B-1,3- LNT, LNFP-I, LNFP-II, LNFP-V, LNDFH- jhp0563 AEZ55696.1 ga actosy transferase I, LNDFH-II, pLNH, F-pLNH I
ATK homologous to B-1,3- LNT, LNFP-I, LNFP-II, LNFP-V, LNDFH- g WP_111735921 ga actosy transferase I, LNDFH-II, pLNH, F-pLNH I futC WP 080473865.1 a-1,2-fucosy - 2-FL, DFL, LNFP-I, LNDFH-I transferase
FucT2 HpUA802 | AAC99764.1 a-1,2-fucosy - 2 -FL, DFL, LNFP-I, LNDFH-I transferase
FucT2 EcO126t | ABE98421.1 a-1,2-fucosy - 2-FL, DFL, LNFP-I, LNDFH-I — transferase
FucT2 Hm12198 | CBG40460.1 a-1,2-fucosy - 2-FL, DFL, LNFP-I, LNDFH-I — transferase
FucT2 Pm9515 | ABM71599.1 a-1,2-fucosy - 2 -FL, DFL, LNFP-I, LNDFH-I transferase
FucT2 HpF57 BAJ59215.1 a-1,2-fucosy - 2 -FL, DFL, LNFP-I, LNDFH-I transferase 0-1,3-fucosy - 2 -FL, 3-FL, DFL, LNFP-I, LNFP-III,
FucT6 3 Bf CAH09151.1 transferase LNFP-V, LNFP-VI, LNDFH-II, F-pLNH 0-1,3-fucosy - 2 -FL, 3-FL, DFL, LNFP-I, LNFP-III,
FucT7. 3 Bf CAH09495.1 transferase LNFP-V, LNFP-VI, LNDFH-II, F-pLNH I 0-1,3-fucosy - 2 -FL, 3-FL, DFL, LNFP-I, LNFP-III,
FucT 3 Am ACD04596.1 transferase LNFP-V, LNFP-VI, LNDFH-II, F-pLNH I a-1,3-fucosy - 2-FL, 3-FL, DFL, LNFP-I, LNFP-III,
MAMA_R764 AGC02224.1 LNFP-V, LNFP-VI, LNDFH-II, F-pLNH a-1,3-fucosy - 2-FL, 3-FL, DFL, LNFP-I, LNFP-III,
Mg791 AEQ33441.1 LNFP-V, LNFP-VI, LNDFH-II, F-pLNH I a-1,3-fucosy - 2-FL, 3-FL, DFL, LNFP-I, LNFP-III,
Moumou 00703 | YP 007354660 LNFP-V, LNFP-VI, LNDFH-II, F-pLNH a-1,3-fucosy - 2-FL, 3-FL, DFL, LNFP-I, LNFP-III, a-1,3-fucosy - 2-FL, 3-FL, DFL, LNFP-I, LNFP-III, fucTlll AY450598.1 a-1,4-fucosy - LNDFH-I, LNDFH-II transferase fucTa AF194963.1 a-1,3/4-fucosy - LNFP-II, LNDFH-I, LNDFH-II transferase
Pd2 6ST BAA25316.1 a-2,6-s ay transferase
PspST6 BAF92026.1 a-2,6-s a y transferase
PiST6 145 BAF91416.1 a-2,6-s a y transferase
PiST6 119 BAI49484.1 a-2,6-s ay transferase
DK 181442 B1 38 on [mr [me [mon
The above-mentioned enzymes enable the biosynthetic production of HMO core structures as well as fucosylated and/or sialylated HMO(s) and its glycosidic derivatives. The genes encoding the above- mentioned transferases have been described in the literature.
Sialic acid catabolic and biosynthetic pathways
In some embodiments, the genetically modified cell, contains a deficient sialic acid catabolic pathway.
By "sialic acid catabolic pathway" is meant a sequence of reactions, usually controlled and catalyzed by enzymes, which results in the degradation of sialic acid. An exemplary sialic acid catabolic pathway described herein is the E. coli pathway. In this pathway, sialic acid (Neu5Ac; N-acetylneuraminic acid) is degraded by the enzymes NanA (N-acetylneuraminic acid lyase) and NanK (N-acetylmannosamine kinase) and NanE (N-acetylmannosamine-6-phosphate epimerase), all encoded from the nanATEK- yhcH operon, and repressed by NanR (http://ecocyc.org/ECOLI). A deficient sialic acid catabolic pathway is rendered in the E. coli host by introducing a mutation in the endogenous nanA (N- acetylneuraminate lyase) (e.g., GenBank Accession Number D00067.1(GL216588)) and/or nanK (N- acetylmannosamine kinase) (e.g., GenBank Accession Number (amino acid) BAE77265.1 (GL85676015)), and/or nanE (N-acetylmannosamine-6-phosphate epimerase, Gl: 947745, incorporated herein by reference). Optionally, the nanT (N-acetylneuraminate transporter) gene is also inactivated or mutated. Other intermediates of sialic acid metabolism include: (ManNAc-6-P) N-acetylmannosamine-6- phosphate; (GIcNAc-6-P) N-acetylglucosamine-6-phosphate; (GIcN-6-P) Glucosamine-6-phosphate, and (Fruc-6-P) Fructose-6-phosphate. In some preferred embodiments, nanA is mutated. In other preferred embodiments, nanA and nanK are mutated, while nanE remains functional. In another preferred embodiment, nanA and nanE are mutated, while nanK has not been mutated, inactivated or deleted. A mutation is one or more changes in the nucleic acid sequence coding the gene product of nanA, nanK, nanE, and/or nanT. For example, the mutation may be 1, 2, up to 5, up to 10, up to 25, up to 50 or up to 100 changes in the nucleic acid sequence. For example, the nanA, nanK, nanE, and/or nanT genes are mutated by a null mutation. Null mutations as described herein encompass amino acid substitutions, additions, deletions, or insertions, which either cause a loss of function of the enzyme (i.e. reduced or no activity) or loss of the enzyme (i.e. no gene product). By "deleted” is meant that the coding region is removed completely or in part such that no (functional) gene product is produced. By inactivated is meant that the coding sequence has been altered such that the resulting gene product is functionally inactive or encodes for a gene product with less than 100 %, e.g. 90 %, 80 %, 70 %, 60 %, 50 %, 40 %, 30 % or 20 % of the activity of the native, naturally occurring, endogenous gene product. A "not mutated" gene or protein does not differ from a native, naturally-occurring, or endogenous coding
DK 181442 B1 39 sequence by 1, 2, up to 5, up to 10, up to 20, up to 50, up to 100, up to 200 or up to 500 or more codons, or to the corresponding encoded amino acid sequence.
Furthermore, the bacterium (e.g., E. coli) may also comprise a sialic acid synthetic capability. For example, the bacterium comprises a sialic acid synthetic capability through provision of an exogenous
UDP-GIcNAc 2-epimerase (e.g., neuC of Campylobacter jejuni (GenBank AAK91727.1) or equivalent (e.g. (GenBank CAR04561.1)), a Neu5Ac synthase (e.g., neuB of C. jejuni (GenBank AAK91726.1) or equivalent, (e.g. Flavobacterium limnosediminis sialic acid synthase, GenBank WP_023580510.1), and/or a CMP-Neu5Ac synthetase (e.g., neuA of C. jejuni (GenBank AAK91728.1) or equivalent, (e.g.
Vibrio brasiliensis CMP-sialic acid synthase, GenBank WP_006881452.1).
A method for the biosynthetic production of one or more HMO(s) or another biosynthetic product
The invention relates to the use of a nucleic acid construct, as well as a genetically modified host cell as described above, in a biosynthetic production of one or more HMO(s). The biosynthetic production is characterized in the way that it utilizes a genetically modified cell, wherein the nucleic acid construct is incorporated as described in detail above, into said cell, whereafter the genetically modified cell is capable of utilizing sucrose as the main and/or the sole, carbon source and/or as the main and/or the sole energy source, preferably as main and/or the sole carbon source and/or as the main and/or the sole energy source.
The method for the biosynthetic production of one or more HMO(s) comprises the steps of: a) providing a heterologous nucleic acid construct according to the invention, b) integrating or transforming the nucleic acid construct into a cell capable of producing one or more HMO(s); c) culturing the cell of b) in a suitable cell culture medium, containing sucrose as the sole carbon source, and d) harvesting the HMO(s) produced in step c).
The heterologous nucleic acid construct of the invention may be incorporated into a cell capable of producing one or more HMO(s) in any suitable method, potentially as described above.
Thus, a preferred embodiment of the invention relates to a method for the biosynthetic production of one or more HMO(s), the method comprising the steps of: a) providing a genetically modified cell according to the present disclosure, b) culturing the cell of a) in a suitable cell culture medium, containing sucrose as the sole carbon source, and c) harvesting the HMO(s) produced in step b).
The method for the biosynthetic production of a biosynthetic product of interest comprising the steps of: a) providing a heterologous nucleic acid construct according to the invention,
DK 181442 B1 40 b) integrating or transforming the nucleic acid construct into a cell capable of producing biosynthetic product of interest; c) culturing the cell of b) in a suitable cell culture medium, containing sucrose as the sole carbon source, and d) harvesting the biosynthetic product of interest produced in step c).
The heterologous nucleic acid construct of the invention may be incorporated into a cell capable of producing one or more HMO(s) in any suitable method, potentially as described above.
Thus, a preferred embodiment of the invention relates to a method for the biosynthetic production of biosynthetic product of interest, the method comprising the steps of: a) providing a genetically modified cell with a heterologous polypeptide according to the present disclosure which is also capable of producing the biosynthetic product of interest, b) culturing the cell of a) in a suitable cell culture medium, containing sucrose as the sole carbon source, and c) harvesting the biosynthetic product of interest produced in step b).
Culturing
During culturing of the genetically modified cell capable of utilizing sucrose as the main and/or the sole, carbon source and/or as the main and/or the sole energy source and capable of producing one or more
HMOXs), according to the invention, the oligosaccharide-producing cell is fed with sucrose that provides energy via glycolysis for growing, reproducing and maintaining its structure. In addition, the sucrose taken up by the cell provides, via the described sucrose catabolism, precursors for the synthesis of the activated sugar nucleotide(s) necessary for the glycosylation process that takes place in the cell, as described above. The internalized carbohydrate acceptor, such as lactose, participates in the glycosyl transferase induced glycosylation reaction, in which a glycosyl residue of an activated nucleotide donor produced by the cell is transferred so that the acceptor is glycosylated. Optionally, when more than one glycosyl transferase is expressed by the cell, additional glycosylation reactions can occur resulting in the formation of the target oligosaccharide. Of course, the cell preferably lacks any enzyme activity which would degrade the oligosaccharide derivatives produced in the cell.
According to the invention, the term “culturing” (or “cultivating” or “cultivation”, also termed "fermentation”) relates to the propagation of bacterial expression cells in a controlled bioreactor according to methods known in the industry.
According to said method the genetically modified cell, preferably a bacterium, more preferably an E. coli, is a strain that is optimized for an industrially profitable transformation like oligosaccharide production, because such a strain generally has no ability to utilize sucrose. Therefore, a polypeptide enabling sucrose utilization should be introduced, using an appropriate expression plasmid or via chromosome integration, converting the sucrose minus cell to a sucrose plus cell as described in detail above.
DK 181442 B1 41
To produce one or more HMO(s), the HMO-producing microorganism as described herein are cultivated according to the procedures known in the art in the presence of sucrose as a, or the main or the sole carbon and as an, the main or the sole energy source, and the produced HMO is harvested from the cultivation media and the biomass formed during the cultivation process. Thereafter, the HMO(s) are purified according to the procedures known in the art, e.g., such as described in WO2015188834,
WO02017182965 or WO2017152918, and the purified HMO(s) are used as nutraceuticals, pharmaceuticals, or for any other purpose, e.g. for research.
Biosynthetic production
A method of the invention relating to the production of one or more biosynthetic products of interest, in particular the production of one or more HMO(s). A method of the invention also encompasses the manufacturing of the biosynthetic product(s) of interest or HMO(s) in large scale productions.
Manufacturing biosynthetic products of interest or HMO(s) is typically accomplished by performing cultivation in larger volumes.
The terms “manufacturing” or “manufacturing scale” or “large-scale production” or “large-scale fermentation”, are used interchangeably and in the meaning of the invention defines a fermentation with a minimum volume of 100 L, such as 1000L, such as 10.000L, such as 100.000L, such as 200.000L culture broth. Usually, a “manufacturing scale” process is defined by being capable of processing large volumes yielding amounts of the HMO product of interest that meet, e.g., in the case of a therapeutic compound or composition, the demands for toxicity tests, clinical trials as well as for market supply. In addition to the large volume, a manufacturing scale method, as opposed to simple lab scale methods like shake flask cultivation, is characterized by the use of the technical system of a bioreactor (fermenter) which is equipped with devices for agitation, aeration, nutrient feeding, monitoring and control of process parameters (pH, temperature, dissolved oxygen tension, back pressure, etc.). To a large extent, the behaviour of an expression system in a lab scale method, such as shake flasks, benchtop bioreactors or the deep well format described in the examples of the disclosure, does allow to predict the behaviour of that system in the complex environment of a bioreactor.
With regard to the suitable cell medium used in the fermentation process, there are no limitations, except that with regard to the invention, the media contains sucrose as the primary carbon and energy source.
Harvesting
The term “harvesting” in the context in the invention relates to collecting the produced HMOXs) following the termination of fermentation. In different embodiments it may include collecting the HMO(s) included in both the biomass (i.e., the genetically modified cells) and cultivation media, i.e., before/without separation of the fermentation broth from the biomass. In other embodiments the produced HMO(s) may be collected separately from the biomass and fermentation broth, i.e., after/following the separation of
DK 181442 B1 42 biomass from cultivation media (i.e., fermentation broth). The separation of cells from the medium can be carried out with any of the methods well known to the skilled person in the art, such as any suitable type of centrifugation or filtration. The separation of cells from the medium can follow immediately after harvesting the fermentation broth or be carried out at a later stage after storing the fermentation broth at — appropriate conditions. Recovery of the produced HMO(s) from the remaining biomass (or total fermentation) include extraction thereof from the biomass (the production cells). It can be done by any suitable methods of the art, e.g., by sonication, boiling, homogenization, enzymatic lysis using lysozyme, or freezing and grinding.
After recovery from fermentation, HMO(s) are available for further processing and purification.
Purification of HMO(s) produced by fermentation can be done using a suitable procedure described in
WO2016/095924, WO2015/188834, WO2017/152918, WO2017/182965, US2019/0119314.
Use of a sucrose hydrolysing enzyme in vitro
Preparation of sugars that are suitable for fermentation-based manufacturing is currently costly and inefficient, as described above. Sucrose is a cost-efficient alternative to other sugars due to its high — abundancy and simple handling. Sucrose is easier prepared for fermentation than for instance glucose, also as described above. Nevertheless, many production cells used in manufacturing are incapable of utilizing sucrose as carbon and energy source sufficiently well, if at all. Thus, one aspect of the invention relates to the use of the invertases of the invention, namely SacC Agal, in the preparation of glucose and fructose from sucrose.
Thus, one embodiment of the invention relates to the use of a polypeptide of any one of SEQ ID NO: 1, or a functional homologue of SEQ ID NO: 1, having an amino acid sequence which is more than 80 % identical to SEQ ID NO: 1, in the production and/or manufacturing of glucose and/or fructose. Another embodiment of the invention relates to the use of a polypeptide of SEQ ID NO: 1, or a functional homologue of SEQ ID NO: 1, having an amino acid sequence which is more than 80 % identical to SEQ
ID NO: 1, in the production of glucose and fructose.
Another embodiment of the invention relates to a method for obtaining glucose and/or fructose from sucrose, the method comprising, a) reacting sucrose with a polypeptide of SEQ ID NO: 1, or a functional homologue of SEQ ID
NO: 1, having an amino acid sequence which is at least 80 % identical to SEQ ID NO: 1, b) extracting said polypeptide from the reaction composition after completion of the reaction, and c) extracting and/or purifying glucose and/or fructose from the reaction composition.
General
It should be understood that any feature and/or aspect discussed above in connection with the — described invention apply by analogy to the methods described herein.
DK 181442 B1 43
The terms Lacto-N-triose, LNT-II, LNT II, LNT2 and LNT 2, are used interchangeably.
The terms nucleic acid sequence and nucleotide sequence are used interchangeably.
The following figures and examples are provided below to illustrate the present disclosure. They are intended to be illustrative and are not to be construed as limiting in any way.
EXAMPLES
Example 1 — The introduction of a single gene, sacC. Agal or bff, in the E. coli DH1 K12 strain confers the ability to grow on sucrose as the sole carbon and energy source
Description of the genotype of strains MP1, MP2, MP3, MP4, MP5 and MP6 tested in growth monitoring assays
Based on the previously described platform strain ('MDO”, MP1) (WO2019/123324A1, the modifications summarised in Table 3 below, were made to obtain the fully chromosomal strains MP2, MP3, MP4, MP5 and MP6.
The strain MP2 can produce the tetrasaccharide HMO, LNnT, while the other strains do not form a product of biotechnological interest. The strain MP2 bears the genes that are responsible for the biosynthesis of LNnT, namely /gfA (encoding a beta-1,3-N-acetyloglucosamine transferase) from N. meningitidis and galT (encoding a beta-1,4-galactosyltransferase) from H. pylori, as well as 4 additional genes conferring the ability to grow on sucrose as the sole carbon and energy source. These 4 genes are organized in 2 operons, scrBR and scrYA, which are controlled by a wild-type sucrose promoter (Pscr) and a synthetic dual promoter (PglpF_SD1-Pscr), respectively.
As mentioned above, the strains MP3, MP4, MP5 and MP6 neither produce an HMO or any other high- value product nor express the scrBR and scrYA operons. Instead, each of these strains bears a single genomic copy of a gene encoding a sucrose hydrolase or invertase, whose expression is driven by the synthetic inducible promoter PglpF. Specifically, the strain MP3 expresses a single PglpF-driven copy of the sacC Msuc gene (Mannheimia succiniciproducens, WO2009078687A2, and NCBI Accession Nr. — AAU37516.1); the strain MP4 expresses a single PglpF-driven copy of the sacA Bsub gene (Bacillus subtilis, WO2009078687A2; and NCBI Accession Nr. WP 010886636.1); the strain MP5 expresses a single PglpF-driven copy of the sacC Agal gene (Avibacterium gallinarum) and the strain MP6 expresses a single PglpF-driven copy of the bff gene (Arthrobacter globiformis IFO 3062).
In the present Example, it is demonstrated how the genomic integration of a single gene, sacC_Agal or bff, in the E. coli DH1 K12 strain confers the ability to grow on sucrose as the main and/or the sole carbon and as the main and/or the sole energy source. The present disclosure also demonstrates that the expression of one of these two genes in the E. coli host can be advantageously used as a strain engineering tool for producing strains that are capable of utilizing different carbon and energy sources, also commonly referred to as flexi-fuel strains, with a presumably improved overall cellular physiology, — which results from the possibly lower metabolic burden that the bff- or sacC_Agal-expressing cells
DK 181442 B1 44 experience compared to cells being equipped with other sucrose ulilization systems. such as the SrBR«
ScrYA system.
Table 3. Genclypes of the strains MP1, MP2, MP3, MP4, MP5 and MP6
Strain ID | Genotype Protein Sequence 1D {GenBank} or sequancs and
SEG ID NO; in seg listing
MP1/MDO | Fe A AendA1 ArecA1 Arla? AgyrAGe Athi-T ginVd4 | na. hsORT7frK-mK-) Alec? wcaF: Plac AnanKETA
AlacA Ameld dwead åmdott
MP2 MDO, x2 GENACT” x1 GalT™, x1 sr BR. xT sor YA. | WP 033011473,1 +
WP 001262061 19
WP 000056853.1 (Sor),
WP 000851082.1 (SerR),
CAA40657.1 (ScrY)
CAA40558.1 (ScrA)
MDO, x1 PglpF-sacC Msuc AAU37516.1
MDO. x1 PgloF-sacA_Bsub WP 0108B8636.1
MDO, x1 PglpF-sacC_Agal WP 1038532101
MP MDO, x1 PglpF-bff BAD18121.1 8 ™GleNACT: beta-1, 3-N-acetyloglucosamine transferase
Gal: bets-1 4-galactosyltransfersse
Description of the protocol applied during growth monitoring assays
The strains disclosed in the present example were screened in 96 well microtiter plates using a 4-day profocol During the first 24 hours, cells were grown fo high densities while in the next 72 hours cells were transferred to a medium containing sucrose as the sole carbon and energy source. Specifically, during day 1, fresh inoculums were prepared using a Luria-Bertani broth containing 20% glucose. After 24 hours of incubation of the prepared cultures at 34 C, cells were transferred to a basal minimal medium (200 ul) supplemented with magnesium sulphate and thiamine to which an initial bolus of 20 % — glucose solution and 15 g/L sucrose solution as carbon source was provided to the cells. After inoculation of the new medium, cells were shaken at 1200 rpm at 28 C for 72 hours. The cells were grown in a batch mode of cultivation in microtiter plates that were compatible with the Varioskan LUX
Multimode Microplate Reader from ThermoFisher Scientific.
Results of the growth monitoring assays
Stains were tested in growth monitoring assays using the 72-hour protocol described above, with the cultures being operated at the batch mode in the presence of sucrose. To evaluate the ability of different strains fo grow on sucrose as a function of their genetic makeup (i.e., expression of different proteins associated with distinct sucrose utitzation systems), the raw data on culiure absærbance {in 600 nm), reported by the Varioskan LUX system, was used to inspect the growth curves on sucrose for the strains — tested. The data analysis software Skanlt was used to extract all these growth curves.
DK 181442 B1 45
As shown in Figure 2, the £ coli host (strain MDO, MP1), which does not express an invertase or sucrose hydrolase is expectedly unable to grow on sucrose (l.e., the strain MP1 serves as a negative control for the experiment). As expecied by results presented in WO2009/078687A2, the expression of the SacA Bsub and SecC. Mauc sucrose hydrolase enzymes makes the MDO strain capable of utilizing § sucrose as the sole carbon and energy source (.e., the strains MP3 and MP4 serve as positive controls for the experiment). The same is true for cells expressing the complex sucrose utilization system consisting of 4 proteins, namely SorB, Ser, SerY and SerA (WO2015/197082) (i.e. the strain MP2 serves also as a positive control for the experiment).
As it is shown in Figure 2, the enzymes of the present disclosure, Sach Agaf and Bf, make the MDO strain capable of utilizing sucrose as well, but each of them shows a characteristic growth profile that is much different from each other but also from the ones generated by strains expressing the sucrose hydrolases mentioned above (MP3 and MP4). Specifically, MDO cells expressing a single genomic copy of the bif gene (strain MP8) show a long lag phase, the end of which is followed by a rapid growth on sucrose leading to a high optical density. On the other hand, MDO cells expressing the sacC_Agal gene 18 from a single genomic copy {strain MPS) reach a high optical density very quickly compared to the other three engineered strains, Le., MP2, MP3, MP4 or MP8 (Figure 2).
The fact that cells expressing the SacC_Agal (or BR} enzyme can outcompete previously known sxtracefiular sucrose hydrolases is surprising and highlights the strength of the present disclosure.
Moreover, it is noteworthy that the sequence identity shared among the previously described extracellular sucrose hydrolases SacA_Bsub and SacC_Msuc (WO2009/07B687A2 and NCBI accession ns ), the intracellular sucrose hydrolase SorB (WO2015/187082 and NCBI accession Nr
WP_000056853.1 and AAUITS18.1, respectively) and the SacC_Agal and Bf enzymes of the present disclosure is jow as shown in table 4 below. Only SacC_Agal and SacC_Msuc enzymes seem to share a bil higher sequence identity, which reaches levels of just below 70% (Table 4}.
Table 4. Sequence identity shared among sucrose hydrolases associated with different sucrose utilization systems, using Emboss-Needle default settings.
Example 2 ~ The SacC_Agal sucrose utilization technology can replace the multi-gene sucross utilization system SorBRYA
Description of the genotype of strains MP2, MPS, MPT and MP8 tested in growth monitoring assays
Based on the previously reported platform strain ('MDO”, MP1), the modifications summarised in Table $ below, were made io obtain the fully chromosomal strains MP2, MPS, MPT and MP8.
DK 181442 B1 46
The strain MP2 can produce the telrasaccharide HMO LNT, while the other sirains do not form a product of biotechnological interest. The strain MP2 bears the genes that are responsible for the biosynthesis of LNnT, namely fgtå (encoding a beta-1, 3-N-acetyloglucosamine transferase) from N. meningitidis and galT (encoding a beta-1 4-galaciosyltransferase) from H. pylod, as well as 4 additional § genes conferring the ability to grow on sucrose as the sole carbon and energy source. These 4 genes are organized in 2 operons, sorBR and scryA, which are controlled by a wild-type sucrose promoter (Pscr) and a synthetic dual promoter {PgipF_SD1-Fscr), respectively,
As mentioned above, the strains MP3, MP4, MPS and MP8 neither produce an HMO or any other high« value product nor express the sorBR and scrYA operons, instead, sach of these strains bears one of — more genomic copiss of the gene encoding the enzyme SacC Agal. Specifically, the strain MPS sxpresses a single PglpF-driven copy of the sacC. Agaf gene; the strain MPT expresses two PgipF- driven copies of the sacC_Agal gene; the strain MP8 expresses three PglpF-driven copies of the sacC_Agal gene,
In the present Example, it was demonstrated that the integration of two PglpF-driven expression cassefles of a single gene, sacC_Agal, into the genome of the & coff DHT K72 strain confers the ability to grow on sucrose as a, of the main or the sole, carbon source and as a, or the main or the sole energy source, and at levels that are higher than other single-enzyms sucrose ulilization systems (e.g.
SacC_Msuc or SacA Bsub), or at least at levels comparable to the established ScrBR-SerY A system. 28 — Table 5. Genolypes of the strains MPS, MPT, MP8 and MP2
Strain ID | Genotype Protein Sequence ID (GanBank) or sequence and SEQ ID
NO: in seg listing
MDO, x1 PaloF-sacC Agal WP T103853210.1
MP7 MPO, x2 PgipF-sacQ Agal WP 103853210.1
MDO, x3 PolpF-sacC Agal WP 103853210,1
MP2 MDO, x2 GicNACT™ x1 GalT™, x1 so BR. | WP. 033811473 1 x7 scryå WP 001262081. 1%
WP 000056853.1 (ScrB),
WP 000851062.1 (Sori),
CTAA40657 1 (ScrY)
CAA40858.1 (ScrÅ ** GleNACT: heta-7,3-N-acetylogiucosamine transferase
Gaff: deta-1,4-galactosyltransfersse
Description of the protocol applied during growth monitoring assays 23 The sirains disclosed in the present example were screened in 96 well microliter plates using a 4-day protocol. During the first 24 hours, cells were grown to high densities while in the next 72 hours cells were transferred to a medium contalning sucrose as the main carbon and energy source. Specifically, during day 1, fresh inoculums were prepared using a Luria-Bertani broth containing 20% glucose. After
DK 181442 B1 47 24 hours of incubation of the prepared cultures at 34 C, cells were transferred to a basal minimal medium (200 uL) supplemented with magnesium sulphate and thiamine to which an initial bolus of 20 % glucose solution and 15 g/L sucrose solution as carbon source was provided to the cells. After inoculation of the new medium, cells were shaken at 1200 rpm at 28 C for 72 hours. The cells were grown in a batch mode of cultivation in microtiter plates that were compatible with the Varioskan LUX
Multimode Microplate Reader from ThermoFisher Scientific.
Results of the growth monitoring assays
Strains were tested in growth monitoring assays using the 72-hour protocol described above, with the cultures being operated at the batch mode in the presence of sucrose. To evaluate the ability of different strains to grow on sucrose as a function of their genetic makeup (i.e., expression of different proteins associated with distinct sucrose utilization systems), the raw data on culture absorbance (in 600 nm), reported by the Varioskan LUX system, was used to inspect the growth curves on sucrose for the strains tested. The data analysis software Skanlt was used to extract all growth curves and execute various calculations, including the specific growth rate on sucrose for each of the strains tested. — As shown in Figure 3, the strain MP5, which bears a single sacC Agal copy, can reach higher optical densities when grown on sucrose compared to strains with two (strain MP7) or three (strain MP8) PglpF- driven genomic copies of this gene. However, the growth rate of the strain MP5 at the early exponential phase of growth is lower than the one of the strains MP7 and MP8 (Figure 4). Moreover, the strains with two (strain MP7) or three (strain MP8) PglpF-driven genomic copies of the sacC_Agal gene show very similar growth profiles (Figure 3) and reach similar specific growth rates during exponential growth (Figure 4).
In conclusion, two PglpF-driven genomic copies of the sacC Agal gene suffice to make the MDO strain capable of utilizing sucrose almost as effective as the strain MP2, which expresses the ScrBR-ScrYA sucrose utilization system. Also, the sacC Agal-conferred ability of E. coli DH1 K12 strain to grow efficiently on sucrose is superior to the one conferred by other single-enzyme sucrose utilization systems (e.g. SacC Msuc or SacA Bsub) both in terms of final optical densities being reached in batch cultures and growth rates reached in the exponential phase of growth (Figures 2 and 3).
In this manner, the present disclosure indicates an efficient strain engineering tool for producing flexi- fuel strains with an improved overall cellular physiology, which results from the presumably low metabolic burden of sacC_Agal-expressing cells.
Example 3 — The SacC Agal sucrose utilization technology in an HMO producing host
In the present example the SacC Agal sucrose invertase was introduced into the LNnT expressing host cell, identified in table 7 as MP2, exchanging the PEP-PTS sucrose system encoded by the scrYA, scrBR genes with two copies of the SacC_Agal gene. Furthermore, the SacC_Agal gene was either placed under control of the PglpF promoter (strains MP9 and MP 10) or the sucrose dependent Pscr
DK 181442 B1 48 promoter (strains MP 11 and MP12). fn addition, the effect of deleting the afsG was tested in strains
MP 10 and MP1{2.
The genotypes of the strains are Bsted in table 7.
Table 7: Genotypes of MP2 and MPO to 14
Strainil | Genotype Protein Sequence ID {GenBank) or seguence and SEG ID
NO: in seq listing
MP2 MDO, x2 GIcNACT x1 GalT*, x1 serBR, | WP 033911473,1% x1 scryA WP 001262081.
WP_000056853.1 (SarB),
WP 000851082.1 (Scr),
CAA40657.1 (ScrY)
CAA40858.1 (ScrA)
MPS MDQ, x2 GIENACT” x1 GafT"" x2 PgipF- | WP 033911473 1" sacc_Agal WP 001262061 1%"
WP. 103853210.1
MP10 MOO, x2 GICNACT"" x1 GafT""" x2 PglpF | WP 033911473.1% sacC_Agal, ApisG WP 001282061, 1%
WP 103853210.1
MP11 MDO, x2 GIONACT x1 Gaf PS. x2 Pser- | WP 033911473, 1% s8c0 Agal, WP 001262081. 1%
WP 103853210,1
MP12 MDO, x2 GleNAcT* x1 GalT™, x2 Psor- | WP 033911473.1% sacC_Agal, 4ptsG WP 0012620681,1%
WP 103853210.1 8 "GlNÅAcT: beta-1,3-N-acetyloghicosamine transferase “Galt: beta-1,4-galactosyltransforase
Fermentation Protocol
The FE. coli sirains were cultivated in 250 ml. fermenters (Ambr 250 Bioreaclor system, Sartorius) starting with 100 ml. of mineral culture medium consisting of 31.2 g/L sucrose and a mineral medium comprised of HaPQs, MgSOu x THO, KOH, citric acid, trace element solution, antifoam and thiamine.
The dissolved oxygen level was kept at 23% by a cascade of first agitation and then aliflow starting at 700 rpm {up to max 4500 rom) and 1 VVM {up fo max 3 VVM). The pH was kept at 8.8 by titration with 8.5% NH.OH solution, The cullivations were started with 2% {v/v} inoculums from pre-cultures comprise of 10 g/l sucrose, (NHAHPO4, KHPO4, MgS0 x THO, KOH, NaOH, citric acid, trace element solution, antifoam and thiamine. After depletion of the sucrose contained in the batch medium, a sucrose containing feed solution was continuously added to the fermenter af a rate that maintained carbon- fimiting conditions, The temperature was initially at 33 © but was dropped to 27 © after 20 hours of feeding. Lactose was added as a bolus addition at feed start of 25% lactose monohydrate solution and then every 32 hours to keep lactose from being a rate limiting factor. The growth, metabolic activity and metabolic state of the cells was followed by on-line measurements of reflectance and CO» evolution rate.
DK 181442 B1 49
Results
The production of LNNT is shown as the molar % of the total HMO produced. The fermentations were done in duplicate except for strain MP10. The data is presented in Figure 5.
Specifically, it can be seen that the strains with expressing sacC Agal under the control of the PglpF promoter (strains MP9 and MP10) produced a higher amount of LNnT compared to the strain expressing the four gene PEP-PTS sucrose system. In particular, the strain which has an additional deletion of the glucose transporter ptsG (MP 10) appear to have the potential to reach very high tittered LNnT production since the fermentation when terminated at 115 h, had not reached a plateau in the LNnT production.
From figure 5 it was confirmed that the cell takes up very little sucrose as shown for the strains expressing sacC Agal under control of the sucrose inducible promoter, Pscr (strains MP 11 and MP 12), which produced significantly less LNNT compared to the strains wherein the sacC Agal expression was under control of the PglpF promoter. However, a positive effect of the ptsG deletion, regulating the glucose uptake is also observed for strain MP 12 over strain MP11.
With respect to strain MP 10, a further analysis was conducted with respect to by-products formation. For the MP 10 strain the lactose was reduced 5.5-fold compared to the remaining lactose after fermentation of the MP2 strain. A reduced amount of lactose following fermentation is favourable since only a limited amount of lactose is allowed in the final product and it is preferable not to have to remove lactose in the down-stream processes following fermentation. Other by-products like LNT-II and pLNnH were also reduced with the MP10 strain compared to the MP2 strain (table 8).
Table 8: By-product formation.
Strain | LNT-IVLNAT pLNnH/LNnT
MP10

Claims (29)

PATENTKRAVPATENT CLAIMS 1. Genmodificeret celle, der er i stand til at producere ét eller flere humane mælkeoligo- saccharider (HMO'er), som omfatter en heterolog nukleinsyresekvens, der koder for en invertase, hvilken invertase er SacC Agal, der omfatter eller består af aminosyresekvensen ifølge SEQ ID NO: 1 eller en funktionel homolog deraf, som har en aminosyresekvens, der er mindst 80 % identisk med SEQ ID NO: 1, hvor cellen endvidere omfatter mindst én yderligere heterolog nukleinsyresekvens, der koder for ét eller flere funktionelle enzymer med glycosyltransferaseaktivitet.1. Genetically modified cell capable of producing one or more human milk oligosaccharides (HMOs) comprising a heterologous nucleic acid sequence encoding an invertase, which invertase is SacC Agal comprising or consisting of the amino acid sequence of SEQ ID NO: 1 or a functional homolog thereof, which has an amino acid sequence that is at least 80% identical to SEQ ID NO: 1, wherein the cell further comprises at least one additional heterologous nucleic acid sequence encoding one or more functional enzymes with glycosyltransferase activity. 2. Genmodificeret celle ifølge krav 1, hvor det endogene glukosetransportsystem er helt eller delvist inaktiveret.2. Genetically modified cell according to claim 1, wherein the endogenous glucose transport system is completely or partially inactivated. 3. Genmodificeret celle ifølge krav 2, hvor ptsG-genet, der koder for en cytoplasmatisk membranglukosepermease, er helt eller delvist inaktiveret.3. Genetically modified cell according to claim 2, wherein the ptsG gene, which codes for a cytoplasmic membrane glucose permease, is completely or partially inactivated. 4. Genmodificeret celle ifølge et hvilket som helst af de foregående krav, hvor nævnte heterologe nukleinsyresekvens omfatter en nukleinsyresekvens, der koder for et signalpeptid, som er i stand til at forbedre den kontinuerlige sekretion af nævnte invertase ind i den genmodificerede celles periplasma og/eller ud i det ekstracellulære medium.4. Genetically modified cell according to any one of the preceding claims, wherein said heterologous nucleic acid sequence comprises a nucleic acid sequence encoding a signal peptide capable of enhancing the continuous secretion of said invertase into the periplasm of the genetically modified cell and/or into the extracellular medium. 5. Genmodificeret celle ifølge krav 4, hvor signalpeptidet er valgt fra tabel 1, fortrinsvis signal- peptidet ifølge SEQ ID NO: 28.5. Genetically modified cell according to claim 4, where the signal peptide is selected from table 1, preferably the signal peptide according to SEQ ID NO: 28. 6. Genmodificeret celle ifølge et hvilket som helst af de foregående krav, hvor invertasen er i stand til at hydrolysere ikke-phosphoryleret saccharose.A genetically modified cell according to any one of the preceding claims, wherein the invertase is capable of hydrolyzing non-phosphorylated sucrose. 7. Genmodificeret celle ifølge et hvilket som helst af de foregående krav, hvor invertasen er i stand til at hydrolysere saccharose til fruktose og glucose i cellens periplasmatiske rum og/eller på dens ekstracellulære side.7. Genetically modified cell according to any one of the preceding claims, wherein the invertase is capable of hydrolyzing sucrose to fructose and glucose in the periplasmic space of the cell and/or on its extracellular side. 8. Genmodificeret celle Ifølge et hvilket som helst af de foregående krav, hvor den heterologe nukleinsyresekvens koder for en episomal og/eller genomisk integreret kopi af invertasen.8. A genetically modified cell according to any one of the preceding claims, wherein the heterologous nucleic acid sequence encodes an episomal and/or genomically integrated copy of the invertase. 9. Genmodificeret celle Ifølge krav 8, hvilken celle omfatter mindst to genomisk integrerede kopier af den heterologe nukleinsyresekvens, der koder for invertasen.9. Genetically modified cell According to claim 8, which cell comprises at least two genomically integrated copies of the heterologous nucleic acid sequence encoding the invertase. 10. Genmodificeret celle ifølge et hvilket som helst af de foregående krav, hvor ekspressionen af nævnte invertase muliggør udnyttelse af saccharose som den vigtigste og/eller eneste carbonkilde og/eller som den vigtigste og/eller eneste energikilde for nævnte genmodificerede celle.10. Genetically modified cell according to any one of the preceding claims, wherein the expression of said invertase enables the utilization of sucrose as the main and/or only carbon source and/or as the main and/or only energy source for said genetically modified cell. 11. Genmodificeret celle ifølge et hvilket som helst af de foregående krav, hvor invertasen ikke transporterer saccharose.A genetically modified cell according to any one of the preceding claims, wherein the invertase does not transport sucrose. 12. Genmodificeret celle ifølge et hvilket som helst af de foregående krav, hvilken celle ikke indeholder et komplet saccharoseudnyttelsessystem.A genetically modified cell according to any one of the preceding claims, which cell does not contain a complete sucrose utilization system. DK 181442 B1 51DK 181442 B1 51 13. Genmodificeret celle ifølge et hvilket som helst af de foregående krav, hvor den heterologe nukleinsyresekvens endvidere omfatter ét eller flere regulatoriske elementer til regulering af ekspressionen af den heterologe nukleinsyresekvens.13. A genetically modified cell according to any one of the preceding claims, wherein the heterologous nucleic acid sequence further comprises one or more regulatory elements for regulating the expression of the heterologous nucleic acid sequence. 14. Genmodificeret celle ifølge krav 13, hvor det regulatoriske element omfatter én eller flere inducerbare promotorsekvenser og/eller en eller flere konstitutive promotorsekvenser.14. Genetically modified cell according to claim 13, wherein the regulatory element comprises one or more inducible promoter sequences and/or one or more constitutive promoter sequences. 15. Genmodificeret celle ifølge et hvilket som helst af kravene 13 eller 14, hvor det regulatoriske element er en promotor valgt fra gruppen bestående af PmgiB 70UTR SD8, PmgiB 70UTR SD10, PmgiB 54UTR, Plac 70UTR, PmgiB 70UTR SD9, PmgiB 70UTR SD4, PmgiB 70UTR SD5, PgipF. SD4, PmgiB 70UTR SD7, PmgiB 70UTR, PgipA 70UTR PglpT 70UTR og PglpF.A genetically modified cell according to any one of claims 13 or 14, wherein the regulatory element is a promoter selected from the group consisting of PmgiB 70UTR SD8, PmgiB 70UTR SD10, PmgiB 54UTR, Plac 70UTR, PmgiB 70UTR SD9, PmgiB 70UTR SD4, PmgiB 70UTR SD5, PgipF. SD4, PmgiB 70UTR SD7, PmgiB 70UTR, PgipA 70UTR PglpT 70UTR and PglpF. 16. Genmodificeret celle ifølge et hvilket som helst af kravene 13 eller 14, hvor det regulatoriske element omfatter en konstitutiv promotor valgt fra gruppen bestående af CP6, PosmY, Pspc, Pbla, Prm1 og Prm2.A genetically modified cell according to any one of claims 13 or 14, wherein the regulatory element comprises a constitutive promoter selected from the group consisting of CP6, PosmY, Pspc, Pbla, Prm1 and Prm2. 17. Genmodificeret celle ifølge et hvilket som helst af de foregående krav, hvilken genmodificeret celle er en prokaryot eller en eukaryot celle.A genetically modified cell according to any one of the preceding claims, which genetically modified cell is a prokaryotic or a eukaryotic cell. 18. Genmodificeret celle ifølge et hvilket som helst af de foregående krav, hvilken genmodificeret celle er valgt blandt en gærcelle fra slægterne Komagataella, Kluyveromyces, Yarrowia, Pichia, Saccharomyces, Schizosaccharomyces eller Hansenula eller blandt en filamentøs svamp fra slægterne Aspargillus, Fusarium eller Trichoderma.18. Genetically modified cell according to any one of the preceding claims, which genetically modified cell is selected from a yeast cell from the genera Komagataella, Kluyveromyces, Yarrowia, Pichia, Saccharomyces, Schizosaccharomyces or Hansenula or from a filamentous fungus from the genera Aspargillus, Fusarium or Trichoderma. 19. Genmodificeret celle ifølge et hvilket som helst af de foregående krav, hvilken genmodificeret celle er valgt fra gruppen bestående af Escherichia sp., Bacillus sp., Lactobacillus sp. og Campylobacter sp.19. Genetically modified cell according to any one of the preceding claims, which genetically modified cell is selected from the group consisting of Escherichia sp., Bacillus sp., Lactobacillus sp. and Campylobacter sp. 20. Anvendelse af en genmodificeret celle ifølge et hvilket som helst af kravene 1-19 til biosyntetisk produktion.20. Use of a genetically modified cell according to any one of claims 1-19 for biosynthetic production. 21. Anvendelse af en genmodificeret celle ifølge krav 20 til biosyntetisk produktion af ét eller flere HMO-'er.21. Use of a genetically modified cell according to claim 20 for the biosynthetic production of one or more HMOs. 22. Fremgangsmåde til biosyntetisk produktion af ét eller flere HMO'er, hvilken fremgangsmåde omfatter følgende trin: a) tilvejebringelse af en genmodificeret celle, der er i stand til at producere ét eller flere humane mælkeoligosaccharider (HMO'er) ifølge et hvilket som helst af kravene 1-19, b) dyrkning af cellen fra a) i et egnet celledyrkningsmedium, der indeholder saccharose som en carbonkilde, c) indhøstning afdet eller de i trin b) producerede HMO'er.22. A method for the biosynthetic production of one or more HMOs, which method comprises the following steps: a) providing a genetically modified cell capable of producing one or more human milk oligosaccharides (HMOs) according to any of claims 1-19, b) culturing the cell from a) in a suitable cell culture medium containing sucrose as a carbon source, c) harvesting the HMO(s) produced in step b). 23. Fremgangsmåde til biosyntetisk produktion af ét eller flere HMO'er ifølge krav 22, hvor invertasen i den genmodificerede celle fra trin a) på egen hånd er i stand til at hydrolysere saccharose til fruktose og glucose på den genmodificerede celles ekstracellulære side og/eller i dens periplasmatiske rum, og hvor ekspressionen af nævnte enzym er tilstrækkelig til at muliggøre udnyttelse af saccharose som carbon- og/eller som energikilde for nævnte genmodificerede celle.23. Method for the biosynthetic production of one or more HMOs according to claim 22, wherein the invertase in the genetically modified cell from step a) is capable of hydrolyzing sucrose to fructose and glucose on the extracellular side of the genetically modified cell on its own and/or in its periplasmic space, and where the expression of said enzyme is sufficient to enable the utilization of sucrose as a carbon and/or energy source for said genetically modified cell. 24. Fremgangsmåde til biosyntetisk produktion af ét eller flere HMO'er ifølge krav 22 eller 23, hvor saccharosen i trin b) er den vigtigste og/eller eneste carbonkilde og/eller energikilde.24. Method for the biosynthetic production of one or more HMOs according to claim 22 or 23, wherein the sucrose in step b) is the most important and/or only carbon source and/or energy source. 25. Fremgangsmåde til biosyntetisk produktion | en genmodificeret værtscelle, der er i stand til at producere ét eller flere oligosaccharider og/eller polysaccharider, hvilken fremgangsmåde omfatter følgende trin: a) tilvejebringelse af en ikke-saccharoseudnyttende (Suc’) værtscelle eller en værtscelle med begrænset og/eller ineffektiv evne til at udnytte saccharose, der er i stand til at producere det ønskede biosyntetiske produkt, b) indføring i nævnte værtscelle af en heterolog nukleinsyresekvens, der koder for en invertase, hvilken invertase er SacC Agal, der omfatter eller består af aminosyre- sekvensen ifølge SEQ ID NO: 1, eller en funktionel homolog deraf, som har en aminosyresekvens, der er mindst 80 % identisk med SEQ ID NO: 1, c) dyrkning af cellen fra b) i et egnet celledyrkningsmedium, der indeholder saccharose som den vigtigste og/eller eneste carbonkilde og/eller som den vigtigste og/eller eneste energikilde, og d) indhøstning af det i trin c) producerede biosyntetiske produkt.25. Method for biosynthetic production | a genetically modified host cell capable of producing one or more oligosaccharides and/or polysaccharides, which method comprises the following steps: a) providing a non-sucrose-utilizing (Suc') host cell or a host cell with a limited and/or inefficient ability to to utilize sucrose capable of producing the desired biosynthetic product, b) introducing into said host cell a heterologous nucleic acid sequence encoding an invertase, which invertase is SacC Agal comprising or consisting of the amino acid sequence according to SEQ ID NO: 1, or a functional homolog thereof, which has an amino acid sequence at least 80% identical to SEQ ID NO: 1, c) culturing the cell from b) in a suitable cell culture medium containing sucrose as the main and/or sole carbon source and/or as the main and/or sole energy source, and d) harvesting the biosynthetic product produced in step c). 26. Fremgangsmåde ifølge krav 25, hvor ptsG-genet af nævnte værtscelle, der koder for en glukosepermease, er helt eller delvist inaktiveret.26. Method according to claim 25, wherein the ptsG gene of said host cell, which codes for a glucose permease, is completely or partially inactivated. 27. Anvendelse af en invertase, der er | stand til at hydrolysere saccharose til glucose og fruktose, i en biosyntetisk produktion, hvor invertasen er SacC Agal, der omfatter eller består af aminosyresekvensen ifølge SEQ ID NO: 1, eller en funktionel homolog deraf, som har en aminosyresekvens, der er mindst 80 % identisk med SEQ ID NO: 1.27. Use of an invertase that is | capable of hydrolyzing sucrose to glucose and fructose, in a biosynthetic production, where the invertase is SacC Agal, comprising or consisting of the amino acid sequence of SEQ ID NO: 1, or a functional homologue thereof, having an amino acid sequence of at least 80% identical to SEQ ID NO: 1. 28. Anvendelse af en invertase ifølge krav 27, hvilken invertase er i stand til at hydrolysere ikke- phosphoryleret saccharose til fruktose og glucose i det periplasmatiske rum og/eller på den ekstracellulære side af cellen, der anvendes i den biosyntetiske produktion.28. Use of an invertase according to claim 27, which invertase is capable of hydrolyzing non-phosphorylated sucrose to fructose and glucose in the periplasmic space and/or on the extracellular side of the cell used in the biosynthetic production. 29. Anvendelse af en invertase ifølge krav 27 eller 28, hvor det biosyntetiske produkt er ét eller flere HMO'er.29. Use of an invertase according to claim 27 or 28, wherein the biosynthetic product is one or more HMOs.
DKPA202270138A 2021-05-17 2022-03-25 Cells capable of producing one or more human milk oligosaccharides (hmos) comprising expression of an invertase, method comprising said cells for biosynthetic production and use of said cells for biosynthetic production; use of an invertase in a biosynthetic production DK181442B1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PCT/EP2022/063313 WO2022243310A1 (en) 2021-05-17 2022-05-17 Novel technology to enable sucrose utilization in strains for biosyntetic production
PCT/EP2022/063314 WO2022243311A1 (en) 2021-05-17 2022-05-17 Microbial strain expressing an invertase/sucrose hydrolase
CN202280035391.3A CN117321071A (en) 2021-05-17 2022-05-17 Microbial strains expressing invertase/sucrose hydrolase
EP22730130.6A EP4341277A1 (en) 2021-05-17 2022-05-17 Microbial strain expressing an invertase/sucrose hydrolase
JP2023565529A JP2024516207A (en) 2021-05-17 2022-05-17 Microbial strains expressing invertase/sucrose hydrolase
EP22730129.8A EP4341276A1 (en) 2021-05-17 2022-05-17 Novel technology to enable sucrose utilization in strains for biosyntetic production

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA202170248 2021-05-17

Publications (2)

Publication Number Publication Date
DK202270138A1 DK202270138A1 (en) 2022-11-29
DK181442B1 true DK181442B1 (en) 2024-01-17

Family

ID=84238056

Family Applications (1)

Application Number Title Priority Date Filing Date
DKPA202270138A DK181442B1 (en) 2021-05-17 2022-03-25 Cells capable of producing one or more human milk oligosaccharides (hmos) comprising expression of an invertase, method comprising said cells for biosynthetic production and use of said cells for biosynthetic production; use of an invertase in a biosynthetic production

Country Status (1)

Country Link
DK (1) DK181442B1 (en)

Also Published As

Publication number Publication date
DK202270138A1 (en) 2022-11-29

Similar Documents

Publication Publication Date Title
US20230109661A1 (en) Hmo production
EP4341277A1 (en) Microbial strain expressing an invertase/sucrose hydrolase
JP2024517696A (en) Identification of α-1,2-fucosyltransferase for in vivo production of pure LNFP-I
US20240327886A1 (en) Methods of producing hmo blend profiles with lnfp-i and lnt as the predominant compounds
DK181442B1 (en) Cells capable of producing one or more human milk oligosaccharides (hmos) comprising expression of an invertase, method comprising said cells for biosynthetic production and use of said cells for biosynthetic production; use of an invertase in a biosynthetic production
US20240102063A1 (en) New major facilitator superfamily (mfs) protein (fred) in production of sialylated hmos
US20230109937A1 (en) New major facilitator superfamily (mfs) protein (fred) in hmo production
JP7331278B1 (en) A novel sialyltransferase for the in vivo synthesis of 3'SL
US20240327885A1 (en) Methods of producting hmo blend profiles with lnfp-1 and 2'-fl as the predominant compounds
DK181683B1 (en) Cells exprssing new sialyltransferases for in vivo synthesis of lst-a, methods using same and constructs encoding said sialyltransferases
US20240279697A1 (en) Enhancing formation of human milk oligosaccharides (hmos) by modifying lactose import in the cell
CN117321071A (en) Microbial strains expressing invertase/sucrose hydrolase
WO2023247537A1 (en) New sialyltransferases for in vivo synthesis of lst-c
DK202200689A1 (en) New fucosyltransferases for in vivo synthesis of lnfp-iii
WO2024175777A1 (en) Product specific transporter for in vivo synthesis of human milk oligosaccharides
WO2024133702A2 (en) New fucosyltransferases for production of 3fl
WO2023166035A2 (en) New sialyltransferases for in vivo synthesis of 3'sl and 6'sl
DK202201202A1 (en) New fucosyltransferases for in vivo synthesis of complex fucosylated human milk oligosaccharides mixtures comprising lndfh-iii

Legal Events

Date Code Title Description
PAT Application published

Effective date: 20221118

PME Patent granted

Effective date: 20240117